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Hematopoietic stem cells (HSC) primarily reside in the bone marrow (BM) and possess the ability of 
self-renewal and differentiation to any progenitor or mature blood cell through hematopoiesis. Adult 
HSCs are found in specialized bone marrow niches that are essential for the regulation of quiescence, 
mobilization and differentiation of HSCs. Multiple studies have attempted to shed light on the 
complex signaling pathways between stromal and hematopoietic cells of the niche at steady state, 
inflammation and disease. Endothelial cells (EC) and perivascular stromal niches are known to illicit 
paracrine signals for the control of HSC maintenance and function. Curative transplantation 
approaches dwell on the effective activation and mobilization of hematopoietic stem and progenitor 
cells (HSPC) to the blood circulation. Current pharmaceutical approaches involve the use of mobilizing 
agent granulocyte-colony stimulating factor (G-CSF). The Angiopoietin/Tie (Ang/Tie) signaling 
pathway is essential for embryonic blood and lymphatic vessel development and maturation as well 
as vessel homeostasis in the adult. Few studies attempted to investigate Ang/Tie signaling in the BM 
stem cell niche. Angiopoietin-1 (Ang1) has been studied in the context of HSC maintenance and 
quiescence in the BM. It has also been shown that Ang1/Tie2 signaling is important for vascular 
recovery following BM irradiation. Besides the well-established role of Ang/Tie signaling in EC, Tie2 
receptor is also known for its expression in HSPC. These findings led to the hypothesis that Ang/Tie 
signaling might impact HSPC in the bone marrow niche.  
The present study investigated Angiopoietin-2 (Ang2) in vivo in the context of HSPC activation, egress 
and mobilization to the periphery. For this purpose, both genetic approaches as well as 
pharmaceutical inhibition of Ang2 were employed. Although Ang2 did effect HSPC egress at steady 
state, Ang2KO mice demonstrated a delayed and reduced HSPC mobilization to the periphery upon G-
CSF stimulation. Further dissection of the phenotype revealed that the absence of Ang2 hindered the 
prompt activation of HSPC rather than the process of mobilization. The bone marrow vasculature and 
its function seemed unaffected by Ang2 at steady state and upon G-CSF mobilization. Further 
assessment of Ang2 function on HSPC was carried out in the context of hematopoietic reconstitution 
upon lethal irradiation. The reduced capability of immune cell reconstitution in Ang2KO mice 
confirmed the ligand’s importance in replenishing the BM. The next focus of the thesis was 
elucidating the roles of Tie1 receptor on ECs in the BM in vivo. The investigation of HSPC egress and 
G-CSF-induced mobilization revealed fewer HSPCs in the periphery. Functional assays on blood 
vessels revealed that subtle changes in the vasculature are responsible for the reduced ability of HSPC 
mobilization in Tie1iECKO mice. Finally, since Tie1 receptor is not only expressed in ECs but also in 
HSPCs, this study involved the investigation of the receptor’s role in progenitor colony formation in 
vitro and BM reconstitution in vivo. Colony forming unit (CFU) assays revealed that Tie1 deletion on 
HSPC (Tie1KO) reduced the cells' ability to form differentiated colonies. Serial and competitive 
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transplantations in mice confirmed the reduced ability of Tie1-deleted HSPC to repopulate the 
myeloid BM compartment of lethally irradiated mice. 
The present thesis sheds lights on the interactions of blood vessels and HSPCs from an ''Ang/Tie-
centric'' perspective. The experiments have unraveled the contribution of the context-dependent 
partial agonist Ang2, and the orphan receptor Tie1 in HSPC egress, mobilization and bone marrow 
reconstitution. These new discoveries are important in elucidating Ang/Tie signaling in the BM and 
potentially contribute to HSPC mobilization research for the treatment of hematological malignancies. 
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ZUSAMMENFASSUNG 
Hämatopoietische Stammzellen (HSC) sind primär im Knochenmark angesiedelt und besitzen die 
Fähigkeiten der Selbst-Erneuerung und der Differenzierung in jede Zelle der Hämatopoese. Adulte 
HSC befinden sich in spezialisierten Knochenmark-Nischen, die ihren Ruhezustand, ihre Mobilisierung 
und ihre Differenzierung essentiell regulieren. Mehrere Studien untersuchten die komplexen 
Signalwege zwischen Stromazellen und hämatopoietischen Zellen in physiologischem, entzündetem 
und erkranktem Kontext. Erhalt und Funktion von HSC werden durch Endothelzellen (EC) und 
perivaskuläre Stroma-Nischen mit parakrinen Signalen kontrolliert. Verschiedene Transplantations-
ansätze basieren auf der Aktivierung von hämatoipoetischen Stamm- und Vorläufer-Zellen (HSPC) und 
ihre Mobilisierung in die Zirkulation, welches hauptsächlich durch die pharmakologische Verwendung 
des HSPC-mobilisierenden Granulozyten-Kolonie-stimulierenden Faktors (G-CSF) hervorgerufen wird. 
Das Angiopoietin/Tie (Ang/Tie) Signalsystem ist essentiell für ein funktionsfähiges Gefäßsystem, da es 
eine wichtige Rolle bei der embryonalen Entwicklung und beim Reifesprozess von Blut- und Lymph-
Gefäßen sowie bei der adulten Gefäß-Homöostase spielt. Nur wenige Studien haben die Ang/Tie 
Signalwege in der Stammzell-Nische des Knochenmarks untersucht. Dennoch bestätigen Experimente 
die Wichtigkeit von Angiopoietin-1 (Ang1) beim Erhalt und beim Ruhezustand der HSC im 
Knochenmark. Neben der bekannten Funktion von Ang1/Tie2 in EC wurde Tie2 auch in HSC 
nachgewiesen. Weiterhin ist das Ang1/Tie2 Signalsystem für vaskuläre Regeneration nach 
Knochenmarksbestrahlungen verantwortlich. Aufgrund dieser Informationen wurde die Hypothese 
formuliert, dass das Ang/Tie Signalsystem einen Einfluss auf HSPC in der Knochenmark-Nische haben. 
In der vorliegenden Arbeit wurde die Rolle von Angiopoietin-2 (Ang2) bei der Aktivierung und der 
Mobilisierung in die Peripherie von HSPC in vivo studiert. Dafür wurden genetische als auch 
pharmakologische Ansätze zur Hemmung von Ang2 etabliert. Obwohl Ang2 keinen Effekt auf die 
Mobilisierung von HSPC im physiologischen Kontext hatte, wurde bei Ang2 Knock-out (Ang2KO) 
Mäusen eine verspätete und verminderte HSPC Mobilisierung in die Zirkulation nach G-CSF 
Stimulierung festgestellt. Weitere Untersuchungen des Phänotyps ergaben, dass der Verlust von Ang2 
eher die direkte Aktivierung von HSPC als den Prozess der Mobilisierung verhinderte. Die 
Knockemarksgefäße und ihre Funktionen blieben sowohl im physiologischen Kontext als auch nach   
G-CSF Stimulierung unbeeinflusst. Nach letaler Bestrahlung bestätigte eine verminderte Immunzell-
Regeneration in Ang2KO Mäusen die Rolle von Ang2 bei hämatopoietischer Regeneration von HSPC. 
Weiterhin wurde in der vorliegenden Studie die Rolle des Tie1 Rezeptors in ECs im Knochenmark in 
vivo erforscht. Untersuchungen der physiologischen sowie der G-CSF-induzierten Mobilisierung von 
HSPC in Tie1 Endothelzell-spezifischen Knock-out (Tie1iECKO) Mäusen wiesen auf weniger HSPC in der 
Peripherie hin. Durch feine Änderungen der Gefäßstruktur reduzierte sich die HSPC Mobilisierung in 
Tie1iECKO Mäusen. Da der Tie1 Rezeptor nicht nur in ECs sondern auch in HSPC exprimiert ist, wurde 
die Funktion von Tie1 bei der Formation von Kolonien in vitro und Knochenmark-Rekonstruktion in 
vivo untersucht. Colony Formation Assays zeigten, dass Tie1 Knock-out in HSPC (Tie1KO) die 
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Formation von differenzierten Kolonien reduzierte. Serielle und kompetitive Transplantationen in 
Mäusen bestätigten, dass Tie1KO die Ansiedlung von HSPC im Knochenmark nach letaler Bestrahlung 
reduziert.  
Die vorliegende Promotion analysiert die Interaktion von Blutgefäßen und HSPC mit dem Ang/Tie 
Signalsystem in Schwerpunkt. Die Einflüsse des kontextabhängigen, partiellen Agonisten Ang2 und 
dem Rezeptor Tie1 auf die Mobilisierung von HSPC und auch auf Knochenmark-Regeneration wurden 
detailliert untersucht. Die gewonnenen Erkenntnisse über die Funktion von Ang/Tie Signalwegen im 
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1. INTRODUCTION 
1.1 THE VASCULAR SYSTEM 
Vertebrate body architecture consists of two highly branched, tree-like tubular networks: the blood 
and lymphatic vessels. Endothelial cells are the building blocks for both networks which are essential 
for efficient and concurrent transport of gas, liquids, nutrients, waster products, signaling molecules, 
cells and heat. The blood vascular system consists of the heart that pumps O2-rich blood into the 
efferent arteries, smaller arterioles and capillary beds. Small-diameter capillaries are where the gas 
exchange takes place before deoxygenated CO2-rich blood and metabolic waste products are carried 
via afferent venules and veins to the lung circuit for replenishment (1, 2). On the other hand, the 
functions of the lymphatic vasculature involve immune surveillance and collection and draining of 
protein-rich fluid back to blood vessels. Upon inflammatory stimuli, immune cells such as 
lymphocytes and antigen-presenting dendritic cells travel via lymphatic vessels towards lymphoid 
organs (3).  
Blood vessels can be generated via two ways: vasculogenesis and angiogenesis. At early stages of 
embryonic development, cells from the mesoderm differentiate into hemangioblasts and then 
migrate forming aggregates to give rise to primitive vessels as part of vasculogenesis (4). Angiogenesis 
on the other hand, is the process through which the expansion of existing vascular networks takes 
place. Angiogenesis can be divided into a series of processes such as EC sprouting, migration, 
proliferation, vessel anastomosis and pruning (2, 5, 6). Endothelial, perivascular and smooth muscle 
cells are essential in order to orchestrate such processes with extensive coordination to ensure vessel 
integrity via vascular remodeling, stabilization and maturation (1, 7).  
1.1.1 Bone angiogenesis 
Bone vasculature is formed almost exclusively by endochondral angiogenesis instead of 
vasculogenesis.  At mouse embryonic day (E) 13,5 to 14,5, already existing blood vessels invade the 
cartilage template and angiogenesis takes place until reaching the plateau at early adulthood (8). 
Initially, the primary ossification center (POC) is determined by onsite chondrocytes which stop 
proliferating, become hypertrophic and secrete pro-angiogenic factors in order to stimulate 
angiogenesis. Consequently, blood vessels invade the POC and form a vascular network while 
simultaneous ossification processes are also taking place (9). Finally, vessels penetrate the epiphyseal 
chondrocytes at both distal ends of the long bones and initiate the formation of the secondary 
ossification center (SOC). Notably, flat bones develop via intramembranous ossification without the 
need for an intermediate chondrocyte template (10).  
Bone vascularization has been shown to be the result of various molecular factors that derive from 
both blood vessels and bone suggesting that the processes of bone angiogenesis and osteogenesis are 
coupled. One of the vital regulators of angiogenesis, VEGFA, is expressed by hypertrophic 
chondrocytes and signals via the VEGFR2 receptor triggering cell migration, proliferation and survival 
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in ECs (11). Hypoxia further activates a chain of intracellular signaling pathways via hypoxia inducible 
factor (HIF). All metabolic gene regulations in chondrocytes are orchestrated by hypoxia since these 
cells function in hypoxic conditions with anaerobic metabolism (12). Matrix remodeling and 
mineralization are carried out by matrix metalloproteases secreted by chondrocytes (e.g. COL2) and 
osteoblasts (e.g. COL1) (13, 14). Finally, Fibroblast growth factors (FGFs) signal through four tyrosine 
kinase receptors (FGFR1-4) and initiate cell survival, proliferation and differentiation.  During 
osteogenesis, FGFR1-2 are expressed in endothelial cells (15) whereas their ligands are secreted by 
chondrocytes and osteoprogenitors (16).   
1.1.2 Structure of bone vasculature 
Early dye-based studies as well as more recent and technologically advanced methods have 
contributed to the understanding of complex organization and functionality of bone vasculature (17, 
18). Such methods include specific antibodies, transgenic fluorescent reporters, confocal and two-
photon microscopy and three-dimensional (3D) reconstruction of imaging data. Long bones are 
calcified, contain the marrow and are highly vascularized except in the growth plate and articular 
cartilage. The BM has been characterized as an organ in which its microvasculature is termed 
“sinusoidal” due to the fact that endothelial cells lack connective tissue covering and are in direct 
contact with the parenchymal cells. The diaphysis is the central core of the bone extending to the 
metaphysis and the epiphysis. Bone vasculature follows a hierarchical order with afferent arteries 
feeding into the capillary network which is drained into a large vein at the center of the diaphysis (19, 
20). In the attempt to classify blood capillaries based on marker expression and functional 
characteristics, two classes of H and L capillaries were identified (21). H capillaries are located in the 
metaphysis and are structured as interconnected tubular columns close to the endosteum. These 
vessels highly express the junction protein, CD31 and the sialoglycoprotein, endomucin (CD31hi 
EMCNhi). Moreover, they are surrounded by perivascular osterix-expressing osteoprogenitor cells.       
L vessels on the other hand, are located in dense branched organizations in the diaphysis and 
correspond to previously mentioned sinusoidal vasculature (22, 23). In terms of marker expression,    
L vessels express CD31 and endomucin yet in lower levels than H vessels (CD31lo EMCNlo). L type 
vessels are also distinct for being surrounded by densely packed HSCs and for extending to the large 
central vein. Arterial blood is supplied to the bone via H vessels in the metaphysis and endosteum 
before entering the L sinusoidal network at the interface between metaphysis and diaphysis and 
finally reaching the large central vein. Consequently, spatially distinct metabolic states can be 
identified in the BM depending on the vasculature. The diaphysis is highly hypoxic due to the 
presence of sinusoidal L vessels and vast number of HSC. On the other hand, the metaphysis is rich 
with arterial vessels and therefore it is oxygenated in the adult mice (20, 24, 25).  
As previously mentioned, bone vasculature is characterized by several types of mural cells. In the 
diaphysis there are two types of perivascular cells surrounding L type sinusoids, namely leptin 
receptor (LEPR)+ cells (26) and CXCL12-abundant reticular (CAR) cells (27). Besides undertaking 
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important roles in HSC maintenance, LEPR+ cells also express PDGFRα yet are negative for distinct 
pericyte markers such as PDGFRβ and NG2. In the metaphysis, as in soft tissues, arteries are 
surrounded by αSMA+ cells which also express NG2 (28). Interestingly, periarteriolar NG2+/nestin-
GFPhigh cells may differentiate to various mesenchymal lineages such as bone, cartilage and adipocytes 
(29, 30).  
1.1.3 Angiopoietin/Tie system 
The Angiopoietin/Tie (Ang/Tie) signaling pathway regulates blood and lymphatic vascular 
development via sprouting angiogenesis, vessel remodeling, endothelial maturation. It plays essential 
roles in vessel permeability, inflammation and cancer development and metastasis (31). Tie1 and Tie2 
receptors form the Tie receptor family and are most predominantly expressed in the endothelium 
(32, 33), yet not exclusively. Studies have identified the presence of Tie receptors in top hierarchical 
HSCs, and Tie2 on monocytes and macrophages (34-38). Tie2 acts as a receptor for the Angiopoietin 
(Ang) family of ligand proteins (Ang1, Ang2 and Ang4) whereas Tie1 is a receptor that is activated via 
Ang-Tie2 signaling (39, 40).  
The “Tie” acronym stands for “Tyrosine kinase with Ig and EGF homology domains” (32). Tie receptors 
are single transmembrane molecules possessing an extracellular ligand-binding domain and a split 
intracellular Tyr kinase domain. Their structure share a high degree of homology with 76% and 33% 
similarity in their intracellular and extracellular domains respectively (41). Both receptors are 
composed of three EGF-like modules flanked by three immunoglobulin (Ig)-like domains and three 
fibronectin type III repeats adjacent to the transmembrane (32, 33). The cytoplasmic region possesses 
kinase domains as well as phosphorylation and protein interaction sites (42) (Fig. 1). The 
angiopoietins consist of an N-terminal region responsible for their multimerization, a coiled-coil 
domain that dimerizes and a C-terminal fibrinogen-like domain that comprises of the Tie2-binding 
region (43, 44). Electron microscopy images have shown that ligands Ang1 and Ang2 are able to form 
dimeric, trimeric, tetrameric and pentameric multimers. More specifically, Ang1 predominantly forms 
tetrameric or higher order assemblies (45) whereas Ang2 exists mostly as dimer. The ligand-receptor 
binding is affected by the Angiopoietin oligomerization status. Ang1 for instance, can bind both 
ligand-binding sites of Tie2 homodimers due to its multimeric structure. On the other hand, due to 
the dimeric conformation of Ang2, the bridging of Tie2 extracellular homodimers is not achieved 
limiting the dimerization and activation of Tie2 (46). Ang2 has therefore been characterized as 











Figure 1: Structure of Tie receptors and Angiopoietin ligands 
A) Tie receptors are highly homologous transmembrane receptor Tyrosine kinases. The extracellular domain 
consists of three immunoglobulin-like (Ig) domains flanking three EGF-like modules and three fibronectin type III 
repeats. The intracellular domain is made up of a split tyrosine kinase module. B) Angiopoietins are secreted 
glycoproteins that consist of an N-terminal coiled-coil domain and a C-terminal fibrinogen-like domain. The 
parallel coiled-coil and superclustering coiled-coil domain assist Ang ligand oligomerization. Ang1 exists most 
commonly in tetramers, wheras Ang2 exists in dimers.  
Embryonic lethality occurs in Tie2 and Tie1 deficient mice at E10.5 and E13.5 respectively. The former 
develop vessel remodeling defects in the plexus of the yolk sac, the brain and lethal heart defects, 
whereas the latter show loss of structural integrity of vascular endothelial cells which results in lethal 
edema and hemorrhage (49). Besides fewer numbers of EC and pericytes as well as poor vessel 
organization, the absence of Tie2 leads to EC apoptosis which leads to lethal hemorrhage (50-52). In 
the case of Tie1 embryonic deficiency, developmental angiogenesis is not disturbed and 
hematopoiesis occurs naturally as opposed to Tie2-deficient mice (53). It is now well accepted that 
Tie1 and Tie2 are important for maintaining the integrity of mature vessels, yet do not play an 
important role in early angiogenic sprouting  (54).  
Ang1 deficiency in embryonic development leads to lethality at E11-E12.5 (50) with similar, yet less 
severe defects as in Tie2 deficiency. The heart of these embryos develops slower with less complex 
ventricular endocardium. Anatomically, the endocardium is collapsed and is not attached to the 
myocardial wall. Endothelial cell lining in the atria is collapsed and the trabeculae are not developed. 
Moreover, vascular defects including a smaller and immature primary capillary plexus and lack of 
proper pericyte coverage contribute to embryonic lethality. Ang1 myocardial overexpression studies 
have identified that the agonist dramatically affects early embryonic mouse development yet does 
not affect vessel structure and heart development in adulthood (55). In the case of Ang2 deficiency, 
perinatal lethality is strain-dependent. Although 129/J background mice die 14 days after birth (56), 
C57BL/6 background mice cope better with only 10% postnatal lethality (57). These mice may develop 
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severe chylous ascites postnatally and their large vessels are poorly organized with deficient smooth 
muscle cell coverage (58). Moreover, intestinal lymphatic vasculature appears disorganized and 
irregular (56). Overexpression of Ang2 has similar effects to Ang1 and Tie2 deficient mice supporting 
the idea that Ang1 acts agonistically on Tie2 whereas Ang2 behaves as an antagonist of the system. 
Interestingly, Ang2 has been shown to exert different effects depending on presence or absence of 
other cytokines.  Notably, Ang2 and VEGF act synergistically inducing angiogenesis; however, in the 
absence of VEGF, Ang2 induces EC apoptosis and vessel regression (48, 59, 60).  
1.1.4 Angiopoietin-1 mediated Tie2 signaling  
At steady state conditions, Ang1 agonistically activates Tie2 signaling in a Tie1 dependent mechanism. 
This process initiates different signaling pathways that orchestrate cell survival, quiescence, 
maturation, EC activation, migration and permeability. Ang1 is constitutively released by perivascular 
cells and binds to Tie2 receptor leading to its dimerization and phosphorylation. The Ang1/Tie2 
complex translocates to cell-cell contacts where the formation of trans-endothelial complexes with 
other Tie1 receptors from adjacent EC. This signals the recruitment of adaptor proteins such as 
growth factor receptor-bound protein2 (GRB2) and the PI3K regulatory subunit p85 which in turn 
activate the AKT pathway. AKT signaling promotes EC survival via the induction of Survivin (BIRC5) and 
endothelial nitric oxide synthase (eNOS), while suppressing apoptotic signaling such as BCL2-
associated agonist of cell death (BAD) and caspase 9 (Casp9) (61-64). Ang1 binding on Tie2 can 
repress Ang2 transcription by inducing the phosphorylation, nuclear exclusion and therefore 
inactivation of the Forkhead transcription factor 1 (FOXO1). Consequently, Ang1/Tie2 signaling drives 
a negative feedback loop for Ang2 expression (65). On the other hand, AKT inhibition can lead to 
FOXO1 dephosphorylation which in turn promotes Ang2 secretion and therefore vascular 
destabilization (66). Moreover, it has also been shown that Tie2 activity is regulated by vascular 
endothelial protein tyrosine phosphatase (VE-PTP) (67). Ang/Tie signaling is highly responsible for 
regulation of vascular permeability. Quiescent, “non- leaky” vessels are characterized by tight and 
adherens junctions. Upon VEGF-mediated permeability, Tie2 induces the sequestration of the non-
receptor Tyr kinase Src. This leads to the activation of Rac family small GTPase 1 (Rac1) which then 
phosphorylates the junctional protein vascular endothelial cadherin (VE-cadherin, CDH5). Finally, β-
arrestin 2 mediates VE-cadherin internalization, degradation and vascular permeability increase (68, 
69). On the other hand, Tie2 signaling leads to small GTPase Ras homolog family member A (RhoA)-
dependent sequestration of Src by mammalian diaphanous (mDia) leading to the anti-permeability 
response of the endothelium (69). Taken together, at resting endothelium Ang1 acts as a vascular 
protector maintaining vessel integrity and inhibiting permeability. In the case of the activated 
endothelium where there are no endothelial cell junctions, Ang1 promotes endothelial cell 
proliferation and migration mediated by the PI3K pathway and FAK phosphorylation (62, 70, 71). 
Ang1-Tie2 signaling is also involved in reducing inflammation via the recruitment of tumor necrosis 
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factor α (TNFα)-induced inhibitory protein 3 interacting protein 2 (ABIN2), which inhibits Nuclear 
factor κB (NFκB) signaling pathway (72, 73). 
The role of Ang1/Tie2 signaling in the recruitment of perivascular cells for vascular quiescence and 
maturation was established early on (31). Although the complete mechanism of this process are yet 
to be uncovered, studies have so far demonstrated that Ang1 agonistic action on Tie2 initiates the 
expression of heparin-binding epidermal-like growth factor (HB-EGF) leading to the migration and 
recruitment of vSMC (74, 75). Moreover, the serotonin pathway is also implicated in Ang1/Tie2-
guided recruitment of vSMC to vessels (76). Finally, Platelet-derived growth factor B (PDGFB) is the 
most well-characterized cytokine released by EC with a pivotal role in pericyte recruitment during 
neovascularization (77). PDGFB is secreted by sprouting EC during angiogenesis in order to bind to 
PDGFRB receptor expressed by mural cells. This leads to the proliferation and migration of pericytes 
contributing to vascular maturation. Notably, there is no molecular evidence for the interaction 
between Ang1/Tie2 and PDGFB/PDGFRB axis.  
1.1.5 Angiopoietin-2 mediated signaling: Agonistic and antagonistic roles 
As opposed to Ang1 orchestrating vascular quiescence, Ang2 is required for sprouting angiogenesis, 
vascular destabilization, remodeling and vessel regression (78). In the event of pro-angiogenic stimuli, 
Ang2 functions antagonistically against Ang1-mediated Tie2 signaling (48). Ang2-mediated signaling 
leads to the formation of a Tie2, FAK and αvβ3 integrin complex that gets internalized, ubiquitinated 
and degraded resulting in EC apoptosis (1). Nevertheless, Ang2 has also been reported to act as a Tie2 
agonist and it has been studied at both basal as well as inflammatory conditions. At steady state, the 
agonistic function of Ang2 leads to Tie2 phosphorylation and low FOXO1 activation, a process 
dependent on the presence of Tie1 receptor. Under inflammatory conditions, Ang2 is released and 
Tie1 is cleaved thereby preventing Ang2 agonistic activity and resulting in vessel destabilization (79, 
80). Besides Tie1, VE-PTP has also been shown to determine the context-dependent actions of Ang2. 
VE-PTP regulates Ang2 antagonistic activity in blood endothelium and therefore its absence from 
lymphatic vasculature enables Ang2-Tie2-mediated lymphangiogenesis (81).  
Furthermore, in the absence of Tie2, Ang2 can induce pro-angiogenic responses via integrins. The 
abundant expression of αvβ3, αvβ5, α5β1 integrins on angiogenic tip cells downregulates Tie2 receptor.  
Ang2 can therefore bind to integrins leading to FAK phosphorylation on Tyrosin397 resulting in Rac 
activation and migration ultimately engaging sprouting angiogenesis at the tip cell front (82, 83).  
1.1.6 Tie1 signaling 
Tie1 was until recently described as an “orphan” receptor. It was discovered in 1992 and its signaling 
remains poorly understood due to the lack of identified specific ligands. Tie1 receptor on EC has been 
described as a doublet of 135 and 125 kilo Dalton (kDa) representing the mature glycosylated cell 
surface receptor and the intracellular non-glycosylated immature receptor, respectively (32). Upon 
inflammatory stimuli, the cleavage of the mature receptor occurs resulting in the shedding of a 100 
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kDa soluble fragment that contains the extracellular domain and a 45 kDa fragment containing the 
transmembrane and intracellular domains which remain within the cell. Tie1 undergoes proteolytic 
processing of its extracellular domain during stimulation with VEGFA, TNFα, LPS, phorbol-12-
myristate-13 acetate (PMA) and other inflammatory cytokines and metalloproteases (84-87). Recent 
reports emphasized the roles of Tie1 ectodomain shedding in Ang/Tie signaling in vivo. Under 
physiological conditions, full length Tie1 supports the agonistic activity of Ang2 on Tie2. Under 
inflammatory conditions, however, Ang2 antagonistic actions are favored by the Tie1 ectodomain 
shedding which leads to reduced Tie2 phosphorylation and expression as well as Ang2 upregulation 
(79, 80). Tie1 can bind to Tie2 in both its full length and truncated form that exist in pre-formed 
heterodimers, suggesting that Tie1 endo-domain contributes to the Tie1-Tie2 complex (67, 88). 
Initially, it was reported that the Tie1-Tie2 hetero-complex is maintained via ectodomain electrostatic 
interactions which interfere with Tie2 activation and clustering. This early model suggested that upon 
Ang1 binding to Tie2, the heterodimer would dissociate allowing for Tie2 activation and clustering 
with other Tie2 receptors. On the other hand, Ang2 binding to Tie2 is not able to dissociate Tie1-Tie2 
hetero-complexes and therefore acts as a competitive Tie2 antagonist (67). Tie1 is therefore 
considered an inhibitory co-receptor for Tie2 signaling which inhibits Ang1/Tie2 mediated AKT and 
MAPK phosphorylation as shown in vitro (89). In an attempt to elucidate Tie1-Tie2 
heterodimerization, two recent studies demonstrated that the binding occurs in a β1 integrin-
dependent manner via the formation of β-sheets connecting the membrane-proximal Fibronectin 
type III domain n3 between receptors (46, 80). Functional in vivo studies have been able to elucidate 
the variety of roles of Tie1 on Tie2 signaling at post-natal retinal vascularization. Endothelial cells 
expressing Tie1 are able to negatively regulate Tie2 and drive tip cell formation. In contrast, stalk cell 
formation is orchestrated by the receptors’ cooperation to sustain Ang1/Tie2 signaling whereas in 
quiescent EC there is almost no Tie1 expression (90). As opposed to Tie2, Tie1 is unable to 
phosphorylate neither other proteins nor itself. The phosphorylation of Tie1 has been shown in 
several studies via the soluble chimeric form of human COMP (cartilage oligomeric matrix protein)-
Ang1 (40, 89, 90). In the absence of Tie2, high concentrations of COMP-Ang1 are sufficient to weakly 
phosphorylate Tie1. Similarly but to a weaker extend, native Ang1 and Ang4 are also able to illicit Tie1 
phosphorylation (40, 90). A chimeric form of Tie1 composed of its original intracellular configuration 
and the extracellular domain of macrophage colony-stimulating factor1 (CSF-1) has been shown to 
activate PI3K-AKT survival and inhibit apoptosis pathways (91). This study introduced the notion that 
Tie1 can potentially transduce signals as Tie2 does. The absence of specific ligands up until very 
recently rendered Tie1 signaling mechanisms unclarified. A very recent study conducted in the Zhou 
lab suggests that LECT2 binds to the extracellular Ig3 domain of Tie1 with a Kd affinity of 0.52 μM (92). 
Binding of LECT2 to Tie1 led to the increase in Tie2/Tie2 homodimers in the expense of Tie1/Tie2 
heterodimers. The authors also demonstrated that LECT2 induces Tie1 dephosphorylation, Tie2 
phosphorylation, activates MAPK/PPAR/MMP/VE-Cadherin signaling pathway and inhibits EC 
migration.   
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1.1.7 Ang/Tie signaling in the bone marrow 
The roles of Ang/Tie signaling in the BM have been the focus of interest for few researchers in the 
past three decades. Early reports had already established that Tie receptors are not exclusively 
expressed in endothelial cells but also immature hematopoietic stem cells (38, 53). Moreover, Ang1 is 
also highly expressed in HSCs, and at lower levels in c-Kit+ hematopoietic progenitors, megakaryocytes 
and leptin receptor+ (LepR+) stromal cells (93).  
Literature contains several patient studies on Ang/Tie and blood malignancies with rather 
contradicting results. Although several studies claim that Tie2 is overexpressed in leukemic blasts of 
AML patients, the impact of Ang1 and Ang2 is not very clear. Some claim that high plasma Ang2 
pretreatment levels benefited overall survival (94, 95), whereas others correlate elevated Ang2 with 
higher risk for relapse in patients with AML and MM (96, 97). Ang1 has been identified as biomarker 
for poor prognosis in patients with MDS (98). Regarding tumor metastasis to the bone, Tie2 has been 
identified as a therapeutic target in harnessing tumor angiogenesis and reducing osteolytic bone 
metastasis in breast cancer (99). Moreover, Tie2-expressing ECs may be therapeutically targeted in 
order to increase hematopoietic reconstitution following myelosuppression (100).  
In terms of Ang/Tie in relation to HSCs, early reports have emphasized the importance of Tie2 
expression on HSCs for maintaining quiescence and evading cell death in the BM. Moreover, such 
HSCs adhered to osteoblasts and Ang1-mediated Tie2 signaling led to cobblestone formation of HSC 
in vitro and the maintenance of in vivo long-term repopulation activity (34). This study was followed 
by a contradicting report that showed that global and cell-specific Ang1 deletion did not affect 
hematopoiesis, HSC maintenance and HSC quiescence in normal mouse. On the other hand, Ang1 
secreted by HSC/HSCP and LepR+ reduced vascular leakiness, yet slowed down niche recovery after 
irradiation (93). Furthermore, monotherapy and co-administration of COMP-Ang1 with 
morphogenetic protein 2 (BMP2) in unstressed mice resulted in enhancement of bone formation and 
angiogenesis effects (101). In vitro studies have also validated that Ang1 is the dominant ligand for 
Tie2 expressed on long term HSCs in BM (102) and that Tie1 is not essential for the generation of 
myeloid and lymphoid lineages (53). In addition, in vivo fetal liver cell reconstitution assays with Tie1 
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1.2 HEMATOPOIETIC STEM CELLS 
Hematopoietic stem cells (HSCs) have the ability to self-renew and differentiate into any progenitor 
and mature blood cell through a process named “hematopoiesis” (Fig. 2). In adults, these rare cells 
are hierarchically at the top of hematopoiesis and are predominantly found in the bone marrow (BM) 
(103). Approximately 4-5x1011 hematopoietic cells are generated daily in the adult BM (104). The 
hematopoietic system is essential for the continuous production of highly specialized cells which carry 
out important functions such as oxygen transport and immune defense. The unique properties of 
HSCs are essential in transplantations for the reconstitution of BM after ablation, injury and infection 
(105-107). On the other hand, properties of self-renewal and differentiation are limited in 
hierarchically lower committed progenitor cells (103). Fluorescence activated cell sorting (FACS) 
strategies have allowed the identification of hematopoietic stem cells and progenitors. Notably, the 
Lineage- Sca-1+ c-Kit+(LSK) scheme in mice identifies a diverse group of cells such as long-term 
repopulating cells (LT-HSC), short-term repopulating cells (ST-HSC) and lineage-committed 
progenitors that lack hematopoietic reconstitution properties (108). LSK cells include both HSCs and 
multipotent progenitors (MPP) and together they are known as hematopoietic stem and progenitor 
cells (HSPC).  
 
Figure 2: Hematopoiesis 
Hematopoiesis is the process by which blood cells including erythrocytes, platelets and white blood cells are 
generated from hematopoietic stem cells (HSC). HSC undergo lineage restriction followed by differentiation to 
lineage-committed hematopoietic progenitors via myelopoiesis or lymphopoiesis. Definitions of acronyms can 
be found under section 7. 
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1.2.1 The BM niche 
The BM is the organ that engulfs several hematopoietic and non-hematopoietic cell types that are 
connected via a highly vascularized and innervated network within long and axial bones (109). In 
mice, all bones support hematopoiesis, yet most HSC research involved long bones. In humans on the 
other hand, the axial skeleton is the major hematopoietic site. This includes the cranium, sternum, 
ribs, vertebrae and ilium. With age, the hematopoietic (red) marrow in human long bones is replaced 
by “fatty” yellow marrow and has reduced hematopoietic activity except in the proximal regions of 
long bones (110).  
Ray Schofield developed the niche hypothesis in 1978 (111) in which stem cells are seen in association 
with other cell types capable of determining their behavior. Around the same time scientists at the 
University of Manchester and hematologist Michael Dexter showed that primitive hematopoietic cells 
ex vivo could be maintained in the presence of mesenchymal “stromal” cell cultures (112). Only a few 
years earlier, Brian Lord formulated the hypothesis that bone regulates hematopoiesis based on the 
observation that primitive cells tended to localize towards the endosteum in long BM cavities (113). 
Experimental evidence on engineered mouse strains confirmed the notion that bone cells create the 
HSC niche. A mouse model with an osteoblastic-specific promoter was initially used in order to delete 
a constitutively active parathyroid hormone receptor (114). Approximately a decade later, another 
study attempted to delete BMPr1α using a specific promoter for primitive and mature osteolineage 
cells (115). The results of both studies provided evidence of bone cells regulating mammalian stem 
cells in vivo, however, failed to clarify whether this effect was direct or indirect. As with any 
interactive system, complicated cross-talk takes place among different cell types in the BM. An 
imbalance caused by one cell type does not necessarily imply a direct effect on another cell type 
(116). Current knowledge suggests the existence of numerous specialized niches for hematopoietic 
stem and progenitor cells comprised of multiple cell types that affect the niche in important as well as 
redundant ways (Fig. 3).  
1.2.1.1 Endothelial cells 
Blood vessels in BM are vital for hematopoiesis. During embryogenesis, HSCs arise from the largest 
artery endothelial cells and remain closely associated with blood vessels throughout development 
(117).  In mice, the idea of a vascular-HSC niche was adopted and supported by imaging of the BM 
and HSC distribution close to the vasculature (30, 118). Blood vessels in the BM can be categorized by 
diameter, morphology and basal lamina structure. Arterioles are variable in size, display a continuous 
basal lamina and are parallel to the long axis. Sinusoids on the other hand are large in diameter, 
display a fenestrated basal lamina and are positioned perpendicular to the long axis. Transitioning 
vessels are small in size, possess a continuous basal lamina and are positioned in the outer 20% of 
marrow volume closest to the bone surface (25, 119). 
Endothelial cells (EC) compose the interior of blood vessel lining producing Notch ligands, CXCL12, SCF 
and pleiothrophin that contribute to regulation of HSC and differentiation of progenitor cells (26, 28, 
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120-124). Moreover, ECs are essential for secreting factors which promote hematopoietic 
regeneration after myelosuppressive stress (121-123). Studies in mice using an endothelial cell-
specific approach (Tie2-Cre or Cdh5-Cre) have explored the importance of genes such as gp130, Scf, 
Cxcl12 and Jag1 regarding HSC maintenance at homeostasis. 
Different types of blood vessels have unique molecular identifiers and are associated with distinct 
perivascular cells. EC-derived Notch signaling within the BM contributes to osteogenesis and 
generation of type H and arterial vessels as well as their coverage by PDGFRb+ mesenchymal cells (24, 
28). Early on, it was believed that hypoxia is an intrinsic characteristic of HSPCs that does not 
determine their choice of localization (125). However, a more recent study demonstrated that the 
arteriolar and sinusoidal permeability to blood plasma influences the levels of reactive oxygen species 
(ROS) in HSCs and therefore their positioning within the BM. In a nutshell, HSPCs localized near 
arterioles have lower ROS levels and maintain a quiescent phenotype compared to highly active 
HSPCs with elevated ROS levels near leakier sinusoids (25). Finally, the vascular niche is association 
with HSC quiescence was the topic of a recent study focusing on age-associated bone metastasis. The 
study elucidated the bone-specific mechanism where upon irradiation and chemotherapy, H blood 
vessels undergo remodeling and promote PDGF signaling and therefore the expansion of pericytes. 
On the other hand, the decline of BM pericytes upon aging is the reason behind loss of quiescence 
and expansion of cancer cells. Reduced blood flow hindered PDGF-B signaling and therefore pericyte 
expansion making metastatic cancer cells more susceptible to irradiation and chemotherapy (126).  
1.2.1.2 Perivascular cells 
The localization of HSC in close proximity to blood vessels suggests the existence of a perivascular 
niche. The study of perivascular niches in the BM has revealed that these cells are highly enriched in 
niche signals and mesenchymal stem cell (MSC) activity. Mesenchymal stem and progenitor cells are 
rare stromal cells (MSPC) with properties such as self-renewal and differentiation into bone, fat and 
cartilage. Transplantations of such cells into recipient mice resulted in the formation of a heterotopic 
hematopoietic niche with resident-derived HSC and donor-derived perivascular CD146+ MSPCs (127). 
In contrast to the notion that HSCs are located close to sinusoids, most nerve fibers are wrapped 
around arterioles and therefore HSC niche cells are not directly innervated (25, 29). The sympathetic 
nervous system (SNS) releases adrenergic signals regulating HSC transfer into the circulation in 
response to circadian rhythm (128, 129). Nerve fibers and the Schwann cells are not required for the 
maintenance of HSCs rather than the generation of hematopoiesis after myelosuppressive stress 
(130, 131). Finally, non-myelated Schwann cells orchestrate the proteolytic activation of TGFb leading 
to HSC maintenance activation (132). 
1.2.1.3 Osteolineage 
Historically, osteolineage cells comprised the first population that was associated with HSC regulation 
since Schofield’s niche concept (111). Moreover, early reports suggested that transplanted HSC-
enriched populations would preferentially re-locate along bone surface (133). Eradication of 
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osteoblasts induced acute changes in hematopoiesis such as failure in adequate lymphoid, erythroid 
and myeloid progenitor numbers (134). Two of the best studied cytokines required for non-cell 
autonomous HSC maintenance are Cxcl12 and SCF. However, deletion of Cxcl12 or Scf in mouse 
mature osteoblasts and progenitors did not significantly affect HSC maintenance suggesting that 
osteolineage cells are not directly involved in this process (26, 116, 120). Other important quiescence 
regulating cytokines expressed in osteoblasts include osteopontin (OPN), a negative regulators of HSC 
pool (135, 136), thrombopoietin (THPO) (137, 138) and Angiopoietin-1 (Ang1) (34) although the latter 
has been questioned by newer studies (93). In conclusion, although osteolineage cells were initially 
hypothesized to play direct roles in HSC maintenance, it is now know that their roles focus on the 
maintenance of committed hematopoietic progenitors in the lymphoid lineage (116, 120, 134, 139).  
1.2.1.4 HSC descendants 
Besides HSC regulation by the stromal compartment, differentiated progeny of HSC may also 
contribute to their regulation. Megakaryocytes are closely associated with sinusoids and therefore 
with HSCs in the BM (140). A major source of TGFb1, a HSC quiescence factor, is the megakaryocytic 
population (141). Studies have shown that conditional deletion of Tgfb1 in megakaryocytes leads to 
HSC proliferation in vivo (142). Similarly, as megakaryocytes are the major source of CXCL4, gene 
deletion gave rise to increased HSC proliferation and activation (143). Lastly, megakaryocytes are also 
responsible for the generation of FGF1, a cytokine that directly affects HSCs in promoting 
regeneration after injury (144). 
Macrophages in the BM are a major source of CXCL12 and consequently, depletion of this cell type 
led to HSPC mobilization (145, 146). Moreover, a subgroup of macrophages expresses CD234 which 
may regulate TFGb-SMAD3 signaling in HSC (147). Another subgroup expresses smooth muscle actin 
(SMA) and cyclooxygenase 2 (COX2) and localize close to HSCs. These cells proliferate in response to 
lipopolysaccharide stimuli and produce prostaglandin E2 which correlates with decreased ROS in HSC 
(148). Lastly, osteoclasts that differentiated from the monocyte lineage have been shown to regulate 
HSC maintenance in bone remodeling via modulating Ca2+ concentrations and releasing signals from 
the bone matrix (149-151).  
A subset of T lymphocytes was initially thought to be contributing in successful allogeneic 
engraftment following BM transplantation (152, 153). Technological advances in intravital microscopy 
assisted in the discovery of the co-localization of allo-HSC with FOXP3+ regulatory T (Treg) cells in the 
endosteum following transplantation (154). Treg cells secrete cytokine IL-10 which promotes donor-
derived HSC survival. The depletion of FOXP3+ Treg cells resulted in rapid exhaustion of donor-derived 
HSC leading to the conclusion that Treg cells are an essential immuneregulatory compartment of the 
HSC niche. Moreover, CD150high Treg cells appear in close proximity to HSCs and contribute in 
maintaining their quiescence state at rest and therefore assisting in allo-HSC engraftment (155). In 
summary, Treg cells protect the BM niche from immune attack and promote survival of transplanted 
allo-HSCs.  
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1.2.2 Localization of HSCs in the bone marrow 
The term “stem cell niche” describes the local microenvironment within an organ in which stem cells 
maintain their undifferentiated, self-renewable state and receive signals that predispose their fate. 
Direct visualization and determination of the HSC niche via fluorescent microscopy has been a major 
challenge due to lack of exclusive markers and the calcified nature of bones. Initial studies were based 
on the transplantation of exogenous GFP-labeled HSPCs and tracking via intravital imaging. These 
methods revealed that HSPCs reside close to the endosteum (156-158). As the signaling lymphocytic 
activation molecule (SLAM) family was discovered as part of HSPC markers (CD48, CD150 and CD244), 
thin BM section imaging revealed that such cells are distributed broadly in close proximity to 
endothelial cells and nestin (Nes)-GFP+ perivascular cells (30, 118). Improvements in 3D imaging and 
visualization lead researchers to identify subsets of quiescent HSCs located adjacent to small 
arterioles. Loss of HSC quiescent state correlated with their distribution away from arterioles (29). A 
whole-mount 3D-imaging based study revealed the existence of a non-arteriolar niche associated 
with megakaryocytes secreting CXCL4 (143). On the other hand, a study using KIT immunostaining 
and Ctnnal1-GFP reporter mice concluded that HSC are randomly distributed in the BM rather than 
strategically placed in arteriolar niches (159). Finally, imaging of myeloid-biased HSCs using von 
Willebrand factor (vWf)-GFP determined that HSC-vWf+ and HSC-vWf- dwell within megakaryocytic 
and arteriolar niches respectively (160). To summarize, the identification of quiescent HSC niches 
within the BM is very complex and often generates contradicting studies due to the variety of used 
markers and methodologies in bone processing and imaging.  
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Figure 3: The bone marrow HSC niche at steady state in adults  
Schematic representation of interactions between various cell types and HSC, at steady state. Blood vessels and 
stromal cells in the BM are considered key regulators of HSC activity and maintenance. Such cell types include 
periarteriolar nestin (Nes)-GFPhigh cells, neural-glial antigen 2 (NG2)- positive cells, myosin heavy chain 11 
(MYH11)-positive cell, perisinusoidal Nes-GFPlow cells, CXC-chemokine ligand 12 (CXCL12)- abundant reticular 
(CAR) cells and leptin receptor (LepR)-positive cells. Moreover, CXCL12-CAR and endothelial cells are sources of 
CXCL12 and stem cell factor (SCF) which are necessary for HSC maintenance (27, 29, 118, 125, 159). Nerve fibers 
(130) and associated non-myelinating Schwann cells (132), megakaryocytes (142, 143), macrophages (145-147, 
161), and osteoclasts (149-151) have also been identified as regulators of HSC maintenance. The interactions of 
HSC and osteoblasts has yet to be elucidated, however it has been suggested that they may be implicated in the 
regulation of lymphoid progenitors (116).  
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1.3 STEM CELL MOBILIZATION AND TRANSPLANTATION 
1.3.1 Hematological malignancies   
The term leukemia derives from the Greek words for white (λευκός) and blood (αίμα) referring to a 
purely descriptive observation of elevated numbers of white blood cells (WBC). Leukemia is 
characterized by the term “blood cancer” which also encompasses lymphoma, myeloma, 
myelodysplastic syndrome and myeloproliferative neoplasm. Leukemia comprises a heterogeneous 
cluster of hematopoietic cancers consisting of biologically diverse subgroups. Leukemia types can be 
divided into acute and chronic depending on the differentiated state of abnormal cells. These groups 
can be further categorized into myeloid and lymphocytic depending on the type of the affected cells. 
Gene expression analysis and next generation sequencing (NGS) have significantly contributed in 
identifying unique biomarkers. These improve diagnosis, prognosis and dictate specific treatment 
approaches that have shaped the classification of leukemia types even further (162). According to the 
World Health Organization (WHO), cancer represents the second most prominent cause of mortality, 
with 8.2 million deaths (13% worldwide) in 2012 and around 14 million people affected every year. A 
recent study on cancer incidence and mortality rates estimated that in 2018 there were around 
230,000 new cases and around 114,000 deaths due to leukemia and lymphoma in Europe (Fig. 4) 
(163).  
 
Figure 4: Estimated numbers of new cancer cases and deaths from cancer by cancer site in Europe in 2018 
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Current treatment approaches for leukemia are determined depending on various patient factors 
such as overall health, rate of disease progression, classification etc. Treatment options include 
chemotherapy and other drug therapies, radiotherapy, immunotherapy, vaccine therapy, blood 
transfusion and stem cell transplantation.  
1.3.2 Hematopoietic stem cell transplantation  
BM transplantation is a curative therapy for hematological diseases involving the replacement of 
patient’s immune system with healthy BM transplant. The first human BM transfusion was pioneered 
in 1939 followed by the first hematopoietic stem cell transplantation (HSCT) in 1957 by E Donnall 
Thomas carving the path towards a standard care procedure for hematologic malignancies (164, 165). 
There are two main approaches to hematopoietic stem cell transplantations namely autologous and 
allogeneic. The first approach involves patients receiving their own stem cells and in the latter stem 
cell graft is provided by a healthy donor. In 2017, out of all completed transplantations; autologous 
hematopoietic stem cell transplantations were carried out almost exclusively for the treatment of 
myeloma, non-Hodgkin’s lymphoma and Hodgkin’s lymphoma. On the other hand allogeneic 
transplantations were performed for the majority of acute myeloid leukemia (AML), acute lymphoid 
leukemia (ALL), myelodysplastic/myeloproliferative neoplasms (MDS/MPN), aplastic anemia, chronic 
myeloid leukemia (CML) and chronic lymphoid leukemia (CLL) (166).  
1.3.3 Hematopoietic stem cell mobilization and homing 
Under homeostatic conditions, HSPCs continuously egress out of the BM into the circulation. The 
boosted recruitment of HSPCs in the circulation in response to exogenous stimuli is termed as 
mobilization. HSPC mobilization is essential in treating patients with hematological malignancies or 
other diseases that require curative BM transplantation. The clinical benefit of targeting the BM 
endothelial barrier in the context of curative transplantations is to enhance cell mobilization of donor 
patients. Equally, patients would benefit from the improved homing of donor BM cells due to the 
loosening of the endothelial barrier. Finally, the opposite strategy would benefit in terms of 
expanding the pool of successfully lodged HSCs by tightening the vessel barrier and preventing their 
egress and differentiation (167).  
The success of BM transplantation also depends on the ability of HSC/HSPC to successfully “home” 
and engraft into recipient’s BM. In order for this to be completed, a number of serial processes take 
place including specific molecular recognition, cell-cell adhesion/disengagement, transendothelial 
migration and replenishment of the eradicated BM stem cell niche (168).  
1.3.3.1 Granulocyte-colony stimulating factor (G-CSF) 
In the past decades, granulocyte-colony stimulating factor (G-CSF) has been the mobilization agent of 
choice in clinical transplantation regimens (169). Yet, the incidence of insufficient G-CSF-mediated 
mobilization in certain individuals still remains significant and poorly explained. More specifically, 
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approximately 10% of allogeneic and 40% of autologous donor patients fails to mobilize sufficient 
amounts of HSPC resulting in treatment failure (170, 171). Endogenous G-CSF is released from 
monocytes, macrophages, endothelial cells and various BM stromal cell populations in response to 
sepsis and other inflammatory conditions (172, 173). It acts on the G-CSF receptor and its responding 
cell types are stromal cells and myeloid progenitors. Upon G-CSF stimulation, the CXCL12/CXCR4 
signaling pathway is engaged for enhanced HSPC proliferation, migration and egress in circulation 
(174, 175). Initially, C-X-C Motif Chemokine Ligand 12 (CXCL12) levels decrease dramatically within 
the BM yet increase in blood circulation possibly due to re-secretion of scavenged CXCL12 levels 
(176). The sympathetic nervous system also plays important roles in G-CSF-mediated mobilization. 
This is apparent due to HSPC expression of both dopaminergic and adrenergic receptors and due to 
the fact that circadian epinephrine secretion affects CXCL12 levels within the BM microenvironment 
(130, 177). Moreover, mice with abnormal sympathetic nerve function fail to downregulate CXCL12, 
leading to unsuccessful mobilization in response to G-CSF (128).  
Proteolytic functions of several factors are also important in HSPC mobilization. Notably, CXCL12 
mediates the secretion of SCF via MMP-9 activation which results in enhanced HSPC egress (178). 
Moreover, the expression of membrane-bound type 1 MMP (MT1-MMP) on HSPC is increased upon 
G-CSF administration and actively contributes to the mobilization process by cleaving CD44 homing 
adhesion molecule (179). Finally, in vitro studies have highlighted the proteolytic activity of 
dipeptidylpeptidase 4 (DPP4) or CD26 and osteoclast-secreted cathepsin K by cleaving CXCL12 (150, 
180). Both pharmaceutical inhibition and genetic deletion of CD26 resulted in hampering of HSPC in 
G-CSF-induced mobilization. This was attributed to the proteolytic activity of CD26 against a group of 
CSF proteins such as GM-CSF, G-CSF, IL-3 and erythropoietin (181-183). Notably, CD26 is expressed 
mainly in endothelial cells and its inhibition contributes to maintaining an intact barrier function 
during stress-induced conditions (184).   
To date, G-CSF is available in several pharmaceutical variants. Most in vivo experimental studies have 
been carried out with filgrastim (Neupogen®). Filgrastim is structurally similar to endogenous G-CSF 
and is produced by recombinant DNA technology in an E.coli expression system. The PEGylated form 
of filgrastim is also available under the generic name PEG-filgrastim (Neulasta®). The advantage of 
PEG-filgrastim lies with its longer half-life making daily injections unnecessary. Lastly, another variant 
of recombinant human G-CSF named lenograstim is synthesized in Chinese Hamster Ovary cells (CHO 
cells) and is identical to the 174-amino acid natural human G-CSF.  
1.3.3.2 Other mobilizing agents  
As previously mentioned, the CXCL12/CXCR4 signaling pathway plays a pivotal role in HSPC 
mobilization. AMD3100 is a CXCR4 chemokine receptor antagonist that was discovered via serendipity 
in an HIV therapeutic targeting screening (185). AMD3100 or Plerixafor (Mobozil®) is indicated for use 
in combination with G-CSF for the collection of HSPC from the blood and subsequent autologous stem 
cell transplantation in patients with poor mobilization and non-Hodgkin’s lymphoma (NHL) or multiple 
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myeloma (MM) (186). Other mobilizing agents that disrupt the CXCL12/CXCR4 pathway are CXCR4 
antagonists T140 and T134 (187, 188). Administration of CXCR4 partial agonists such as met-SDF-1β, 
CTCE-0214 and CTCE-0021 has also been associated with mobilization due to desensitization and 
reduced surface expression of the CXCR4 receptor (189, 190). 
The interaction between VLA-4 and VCAM-1 has also been shown to affect HSPC mobilization. 
Targeting strategies involve antibodies against VLA-4 (191, 192)and VCAM-1 (193, 194). Finally, 
monotherapy or combination of GM-CSF with G-CSF is contraindicated nowadays due to inadequate 
number of required mobilized CD34+ cells and high toxicity (195-197).  
1.3.4 Vascular regulation of HSPC trafficking 
Endothelial cells are front-line responders to HSPC mobilizing agents due to the expression of sensory 
receptors which are majorly involved in the mobilization process (Fig. 5). CXCR4 and β-adrenergic 
receptors have been identified as key regulators of HSPC quiescence, BM retention, egress and 
mobilization processes (198-200).  
 
Figure 5: Steady state and G-CSF-induced HSPC mobilization 
G-CSF administration favors HSPC migration to the periphery via the redelivery of CXCL12 from the BM to the 
sinusoid by the EC-expressed CXCR4 receptor. Meanwhile, CD26 receptor levels increase on ECs driving NPY 
cleavage into its truncated form and binds with higher affinity to NPYR2/5. NPY receptor activation leads to 
VE-cadherin internalization, degradation and therefore increased overall vascular permeability. The loosening 
of the vascular barrier further activates HSPCs by increasing intracellular ROS levels, HSPC motility and HSPC-
expressed CXCR4 as a response to the CXCL12 gradient.    
HSPC egress and mobilization has been suggested to be mediated by sinusoidal vessels due to their 
distinct properties compared to other types of vessels. In contrast to sinusoids, arterioles differ in 
integrity properties and higher expression of adherens junction (VE-cadherin) and tight junction 
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markers (ZO-1 and JAM-A) (25). Furthermore, sinusoids display higher permeability as shown by dye 
penetration assays and exhibit much lower blood flow and sheer rates compared to arteries (25). Cell 
trafficking processes such as deceleration, adhesion, rolling and transendothelial migration may only 
occur in low flow speed and shear rate environment such as the sinusoids.  
Upon mobilization stimulus, ECs actively relocate CXCL12 from BM parenchyma to vessel lumen which 
is in direct contact with blood circulation (199, 200). Moreover, it was recently shown that BM 
vascular permeability plays an essential role in regulating activation and induction of HSPC motility via 
enhanced intracellular ROS in response to CXCL12 (25). Taken together, vascular permeability of the 
blood-BM barrier affects BM homeostasis and regulates HSPC fate.  
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2. AIMS OF THE THESIS 
Hematopoietic stem (HSC) and progenitor cells (HSPC) represent a pool of ancestor cells which 
possess the ability of self-renewal and multi-lineage differentiation. Postnatally, the primary source of 
HSC resides within the bone marrow (BM) in a tightly controlled niche that regulates their quiescence, 
proliferation, and differentiation and subsequent mobilization (116, 201, 202). The recurrent 
localization of HSC in close proximity to blood vessels suggests the presence of a niche constituted of 
endothelial and perivascular cells throughout the BM. Consequently, several reports have emphasized 
the importance of the vascular component within the hematopoietic niche in regulating 
hematopoiesis through the expression of surface markers and upregulation of angiocrine factors 
(202). Previous studies revealed that the Ang1/Tie2 signaling pathway plays a critical role in 
maintaining the quiescent state of HSC (34). More recent data also revealed that deletion of Angpt1 
gene from HSC accelerated vascular and hematopoietic recovery following irradiation, while also 
inducing vessel leakiness.  
The aim of the thesis was to investigate roles of Ang2 and Tie1 receptor in endothelial cells as well as 
hematopoietic stem and progenitor cells within the BM niche in vivo. Specifically, the aims focus on  i) 
deciphering the roles of Ang2 in the context of G-CSF-induced mobilization and BM reconstitution and 
ii) investigating the roles of endothelial-specific and HSPC-specific Tie1 receptor in terms of HSPC 
mobilization, vascular function and BM reconstitution potential following lethal irradiation. 
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3. RESULTS  
3.1 HSPC kinetics of G-CSF-induced mobilization in C57BL/6 mice 
Prior to investigating of the roles of Angiopoietin-2 and Tie1, it was necessary to establish a robust 
working model of G-CSF-induced HSPC activation and mobilization to the periphery. For this purpose, 
8-12 week old female C57BL/6 mice were subjected to a single subcutaneous injection of PEGylated 
recombinant G-CSF (Neulasta®) at a dose of 100 μg in 100 μl on day 0. Meanwhile, age-matched 
control mice received 100 μl saline solution (NaCl) subcutaneously. G-CSF exists in several 
pharmaceutical formulation variants; however, the choice of PEGylated formulation was made based 
on the longer half-life and therefore the advantage of single-dose administration. This prevented 
unnecessary dosing variations and animal burden entangled with daily injections. Several 
experimental time points were investigated in order to examine G-CSF kinetics and decide on the 
appropriate termination time-point. BM, spleen and blood were collected at the end of experiment 
and processed for analysis with flow cytometry. Gating strategies involved the isolation of viable 
immune single cells of which Lineage- (Lin-), Lineage- Sca-1+ c-Kit+ (LSK), multipotent progenitors 
(MPP), short term HSC (ST-HSC) and HSC (or LSK-SLAM) were further distinguished. The term 
“lineage” refers to mature immune cells distinguished by the following surface markers: CD3, CD8a, 
Ter119, CD11b, CD45R. For the purpose of the thesis the term “hematopoietic stem progenitor cell” 
or “HSPC” corresponds to LSK population. The term “hematopoietic stem cell” or “HSC” corresponds 
to the LSK CD48- CD150+ or LSK-SLAM population.  
 
Figure 6: Experimental model and gating strategy of G-CSF-induced HSPC mobilization via flow 
cytometry 
Experimental animals received one dose of 100 μg PEGylated recombinant G-CSF (Neulasta®) subcutaneously at 
day 0. BM, spleen and blood were collected at the end of experiment and underwent processing for analysis via 
flow cytometry. (abbreviations see text) 
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Upon G-CSF administration, the Lin- population ratio in the BM gradually decreased suggesting a shift 
towards differentiation to more mature immune cells (Fig. 7A). The HSPC ratio gradually increased 
reaching a peak on day 3 which reflected an increase in HSPC proliferation and the subsequent 
mobilization to the circulation and spleen (Fig. 7B). Within the HSPC compartment, there was an 
increase in MPP cells at the expense of hierarchically primitive LSK CD48- CD150+ cells (Fig. 7C-D). The 
Lin- population in spleen was not significantly altered following G-CSF administration (Fig. 7E). 
However, within the Lin- population, a gradual increase of HSPC compartment took place starting on 
day 3 due to the onset of mobilization from the BM (Fig. 7F). Total body weight and spleen weight 
were recorded. Upon G-CSF administration, mice developed splenomegaly which is one of the well-
known side-effects of mobilizing agents (Fig. 7G-H). Finally, similar to BM, the detected Lin- 
population ratio in the blood was significantly reduced on day 3 after G-CSF administration (Fig. 7I) 
whereas the HSPC population was significantly increased reflecting the onset of mobilization to the 
periphery. Notably, HSC reside within the BM and are therefore not found in spleen or blood even 
after G-CSF administration. Having established the HSPC activation and mobilization model, the 
experimental termination time-point (day 3) was also decided for the subsequent scientific 
experiments.  
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Figure 7: Establishment of G-CSF-mediated HSPC expansion in the bone marrow and mobilization 
Analysis of A) Lineage-, B) HSPC, C) MPP and D) HSC population ratios in the BM via flow cytometry. Population 
ratios of E) Lineage- and F) HSPC cells in spleen. G) Timeline of spleen weight increase upon G-CSF treatment 
and H) representative image of a spleen treated with NaCl and with G-CSF (d3). Population ratios of I) Lineage- 
and F) HSPC cells in blood. Data are shown as mean±sd (n=3-4; Mann-Whitney test, *, p<0.05). (abbreviations 
see text) 
In order to assess how G-CSF stimulation affects Ang/Tie signaling, blood serum and HSPCs were 
collected for C57BL/6N mice at different time-points (Fig. 8A). G-CSF administration resulted in the 
gradual increase of Angiopoietin-2 protein concentration from steady state to day 6 (Fig. 8B). Relative 
Angpt1 expression was measured via qPCR in sorted HSPCs at different time-points upon G-CSF 
injection. Administration of G-CSF resulted in gradual downregulation of Angpt1 on HSPCs (Fig. 8C). In 
conclusion, a G-CSF-induced HSPC activation and mobilization model was established in order to carry 
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Figure 8: Further characterization of experimental model 
A) Schematic representation of experimental model. C57BL/6N mice were treated with G-CSF and sacrificed at 
different time-points. B) Serum Ang2 protein concentration detected via ELISA (n=5-6; ANOVA-Kruskal-Wallis, *, 
p<0.05) and C) relative Angpt1 expression in sorted HSPC (5000 LSK cells/mouse) at consecutive time-points 
upon G-CSF administration. Gene expression is normalized to Hprt1 expression. (n=3-4; ANOVA-Kruskal-Wallis, 
*, p<0.05). Data are shown as mean±sd.  
3.2 HSPC expansion is reduced in Ang2KO mice treated with G-CSF 
The strong increase in Ang2 protein concentration in the serum upon G-CSF administration 
hypothesized the possible contribution of the ligand to the mobilization process. In order to 
investigate this, mice with global deletion of the Angpt2 gene in C57Bl/6N background (Ang2KO), 
kindly provided by Dr. Gavin Thurston, were used. The Ang2KO mouse line breeding strategy involved 
crossing heterozygotes (Ang2+/-), which gave rise to further heterozygotes and homozygotes with and 
without the gene locus (Ang2+/+ and Ang2-/-). Ang2+/+ littermates were used as controls (Wildtype, 
WT). The characterization of HSPC kinetics upon G-CSF stimulation was carried out (Fig. 9A).  
At steady state, absolute numbers of BM HSPCs in WT and Ang2KO mice were comparable (Fig. 9B). 
Moreover, hematological analysis via Hemavet counter on WT and Ang2KO revealed comparable blood 
cell composition (Fig. 9 I-J). Whereas BM HSPC absolute numbers increased gradually in WT animals 
and peaked on day 3, the increase in HSPC absolute numbers in BM and spleen of Ang2KO mice was 
reduced and delayed (Fig. 9B-C). This expansion and mobilization deficiency was not visible in blood 
until day 6 (Fig. 9D). Blood cell counts in WT and Ang2KO littermates were comparable during both 
homeostasis and G-CSF-induced mobilization. This indicated that Ang2 affected HSPC expansion and 
mobilization, but not their differentiated progeny within the assessed time frame (Fig. 9E-G). 
Moreover, HSC numbers in G-CSF treated WT and Ang2KO mice were also comparable (Fig9. H), 
suggesting that Ang2 was not critical for HSC expansion but rather that of multipotent progenitors 
(MPP).   
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Figure 9: Loss of Ang2 decreases G-CSF induced HSPC expansion and mobilization 
A) Schematic representation of experimental model. WT and Ang2KO mice were treated with 100μg human 
PEGylated G-CSF and sacrificed at different time-points. Analysis was performed on BM, spleen and blood with 
flow cytometry. (B) Absolute number of HSPCs in WT and Ang2KO mice at the indicated time-points post-
treatment with G-CSF in the BM, (C) spleen and (D) blood (n=4-9; Mann-Whitney test,*, p<0.05 and **, 
p<0.01). (E) Absolute numbers of blood lymphocyte, (F) neutrophil and (G) monocyte populations in WT and 
Ang2KO mice at steady state and G-CSF treatment timeline assessed by Hemavet counter (n=4; Mann-Whitney 
test). (H) Absolute number quantification of HSC in WT and Ang2KO mice at steady state and treatment with G-
CSF (day 3) (n=4-6; Mann-Whitney test). (I) Hematological profile of WT and Ang2KO mice at steady state and 
(J) percentile representation of distinct blood cell types using Hemavet counter. Data are shown as mean±sd 
(n=8; Mann-Whitney test; *, p<0.05 and **, p<0.01). 
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The pharmacological inhibition of Ang2 was employed in order to validate the genetic approach.  
C57BL/6N mice were injected i.p. with either neutralizing mouse anti-Ang2 antibody or rat IgG (Eli 
Lilly) at 20mg/kg per mouse twice in a week (Fig. 10A). Similar to the Ang2KO genetic mouse model, 
steady state absolute HSC and HSPC numbers were comparable in both WT and Ang2KO mice. 
However, G-CSF stimulation resulted in the reduced expansion of HSC and HSPC within the BM (Fig. 
10B-C). The pharmacological inhibition of Ang2 also resulted in a reduced number of HSPCs mobilizing 
to the spleen (Fig. 10D). Yet this phenomenon was not detectable in blood (Fig. 10E).  
 
 
Figure 10: Pharmacological inhibition of Ang2 results in reduced HSPC and HSC in G-CSF-induced 
expansion and mobilization to the spleen 
(A) Experimental setup of IgG/Ang2 neutralizing antibody administration at steady state and G-CSF induced 
mobilization (day3). (B) HSC and HSPC absolute number quantification in (C) BM, (D) spleen and (E) blood. Data 
are shown as mean±sd (n=6-10; Mann-Whitney test, *,p<0.05). 
In conclusion, Ang2 affected HSPC within the BM resulting in delayed mobilization to the spleen up 
until day 4 prior to catching up. The reduced G-CSF-mediated HSPC activation in Ang2KO mice supports 
the paracrine antagonistic role of Ang2 in the BM niche and pharmacological data could confirm these 
findings.  
3.3 HSC and HSPC proliferation is reduced in Ang2KO mice 
To examine the underlying cause for the poor ability of Ang2KO mice to trigger HSPC activation, the 
proliferative potential of HSPC and HSC was assessed in WT and Ang2KO mice. Ki67/Hoechst33342 
staining identified reduced fractions of HSPC and HSC in the S/G2/M phase in Ang2KO mice during 
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steady state and upon G-SCF mobilization (Fig. 11A-B, D). Likewise, the HSC retention factor Cxcr4 was 
up-regulated in HSC and HSPC in Ang2KO (Fig. 11C-E). HSC sorted from Ang2KO mice also expressed 
more Cdkn1a at mRNA level (Fig. 11E), which interferes with cell cycle progression and has also been 
observed to be elevated in HSC upon Ang1 overexpression (203). HSPC of Ang2KO mice expressed 
enhanced levels of Tek/Tie2 (Fig. 11C), which might contribute to increased quiescence of HSPC and 
has also been shown to be increased in HSC cultured with Ang1 (102). Thus, absence of Ang2 reduced 
HSPC activation by restricting cell cycle entry. In order to investigate whether Ang2 affected the 
mobilization process, WT and Ang2KO mice were treated with AMD3100, a CXCR4 inhibitor and 
,therefore, a rapid stem cell mobilizing agent. The absolute numbers of mobilized HSPC detected in 
blood was comparable in both groups suggesting that Ang2 did not affect the mobilization process.  
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Figure 11: Loss of Ang2 
disrupts HSPC and HSC 
quiescence 
(A) Gating strategy for cell cycle 
analysis of HSPCs with 
Ki67/Hoechst. BM HSCs and 
HSPCs were analyzed for the 
presence of the proliferation 
marker Ki67 and counterstained 
with Hoechst H33342 for cell cycle 
analysis. (B) Percentages of sorted 
BM HSPCs and (D) HSCs in G0/G1 
and S/G2/M phase in G-CSF-
treated (day 2) and NaCl treated 
Ang2KO and WT mice. (C) Target 
gene expression analysis in HSPCs 
and (E) HSCs at steady state (n≥ 3; 
Mann-Whitney test,*, p<0.05 and 
**, p<0.01). (F) Absolute numbers 
of HSPCs in blood of WT and 
Ang2KO mice one hour after 
AMD3100 administration. Data 
are shown as mean±sd (n=7-8; 
Mann-Whitney test). 
 
In order to exclude the possibility of vascular defects and further validate that Ang2 acts in a 
paracrine manner on the activated HSPC, we functionally assessed vessel leakiness ex vivo via dextran 
permeability assay. Sinusoidal vasculature characterization on G-CSF treated mice (day 3) yielded 
comparable vessel area and vessel density in WT and Ang2KO mice (Fig. 12A). Merged confocal images 
demonstrate the co-localization of dextran-FITC with endomucin+ vessels in both experimental groups 
suggesting that Ang2 absence does not alter vessel area and density (Fig. 12B-C). Quantification of 
extravasated dextran-FITC in the diaphysis and epiphysis of femurs resulted in comparable 
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Figure 12: Bone marrow vasculature and dextran extravasation are unaffected by the absence of 
Ang2 upon G-CSF treatment  
(A) Representative confocal images of dextran-FITC 70kD (green), endomucin+ (red) sinusoidal vessels in the 
femur diaphysis region. Scale bar indicates 100um. (B) Vessel area and (C) vessel density quantification. WT and 
Ang2KO femur (D) diaphysis and (E) epiphysis quantification of extravasated dextran. White arrows indicate 
dextran-FITC and endomucin co-localization. Data are shown as mean±sd (n=4-6; Mann-Whitney test). 
3.4 Niche derived Ang2 contributes to bone marrow reconstitution after 
irradiation.  
To further investigate the role of paracrine Ang2 signaling, transplantation experiments were carried 
out in order to assess the hematopoietic reconstitution efficiency. Donor BM cells from CD45.1 mice 
were transplanted into lethally irradiated WT and Ang2KO congenic mice (Fig. 13A). This resulted in 
overall reduced reconstitution efficiency in the Ang2KO mice translating in fewer circulating WBC (Fig. 
13B) as shown by Hemavet counter. More specifically, in the absence of stromal Ang2, the 
repopulating lymphocytes (Fig. 13D) and monocytes (Fig. 13E) were fewer in absolute numbers 
compared to WT mice. This effect was not observed in neutrophils (Fig.  13C). These results were 
further validated by blood flow cytometry analysis with neutrophilic, T-cell and B-cell markers (Fig. 
13F-H). Furthermore, engraftment efficiency was quantified by flow cytometry in blood (Fig. 13I). 
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Percentages of donor-derived (CD45.1+) immune cells were not significantly altered in CD45.2+ 
recipients 18 weeks after transplantation (Fig. 13J). Within the donor-derived immune cells, there was 
no selective advantage in myeloid or lymphoid population fractions (Fig. 13K-L). These data 
demonstrate that the absence of Ang2 from BM stroma resulted in defects in hematopoietic 
reconstitution, but did not play a role in hematopoietic engraftment.  
 
Figure 13: Niche-derived Ang2 affects bone marrow reconstitution in lethally irradiated mice 
(A) BM cells from CD45.1 donor were transplanted into WT and Ang2KO lethally irradiated recipient mice. (B) 
Total white blood cell count in WT and Ang2KO mice throughout BM reconstitution process. (C) Neutrophil, (D) 
lymphocyte and (E) monocyte populations assessed via Hemavet counter. Blood (F) CD45+, CD11b+, Gr-1+, (G) 
CD45+, CD3+ and (H) CD45+,CD19+ cell populations assessed by flow cytometry throughout BM reconstitution. (I) 
Gating strategy for assessment of engraftment efficiency. (J) Engraftment efficiency percentage indicating 
CD45.1+ donor derived cells in blood at the end of the experiment (week 18). (K-L) Donor derived myeloid 
(CD45.1+, CD11b+, Gr-1+) and lymphoid (CD45.1+, B220+, CD4+, CD8+) cell population percentages. Data are 
shown as mean±sd (n=5-8; Mann-Whitney test, p<0.05 and **, p<0.01).  
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3.5 Endothelial Tie1 deletion delays HSPC egress and G-CSF-induced 
mobilization 
The approach for investigating the role of BM endothelial Tie1 in HSPC egress and mobilization 
involved the breeding and use of an inducible EC-specific Tie1 knock-out mouse line (Tie1iECKO). Since 
constitutive Tie1 deletion is embryonically lethal, Tie1flox/flox mice were generated by Dr. Scott Baldwin 
using the Cre/loxP system to induce conditional deletion of the first coding exon of Tie1 (204). In 
order to obtain Tie1 endothelial specific deletion following tamoxifen administration, Tie1flox/flox mice 
were crossed with inducible Tg(Cdh5-cre/ERT2)1Rha(Cdh5CreERT2) mice (205). Tie1flox/flox mice were 
used as controls (Wildtype, WT). For all experiments, Tie1 deletion efficiency was evaluated by qPCR 
in total tissue RNA lysates. Mice with less than 35% Tie1 deletion were excluded from analyses.  
 
Figure 14: Targeting strategy of the Tie1 locus 
Ve-CadherinCreERT2 mice were bred with Tie1flox/flox mice to achieve EC-specific receptor deletion.  
In the attempt to assess the importance of endothelial cell Tie1 in the process of HSPC egress and     
G-CSF-induced mobilization, mice were induced with tamoxifen and either saline or G-CSF was 
administered subcutaneously. On day 3, mice were sacrificed and flow cytometry analysis was 
performed in BM, spleen and blood (Fig. 15A).  
At steady state, the absolute number of HSPCs in BM was unchanged in Tie1iECKO mice compared to 
WT littermates (Fig. 15B). However, a reduced number of HSPCs egressed to the spleen (Fig. 15C). 
Similarly, upon endothelial cell Tie1 deletion and G-CSF stimulation, the number of HSPCs within the 
BM remained comparable between the groups (Fig. 15D). Yet, in the case of HSPC mobilization to the 
periphery, there was a significant decrease in the number of HSPCs in Tie1iECKO mice (Fig. 15E-F). It was 
previously showed that Ang2 affected HSPC expansion. In the case of Tie1iECKO an HSPC mobilization 
phenotype was observed. This suggested that Tie1 deletion affected BM vasculature in restricting 
access of HSPC to the blood stream and eventually the spleen during G-CSF-induced mobilization.  
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Figure 15: Endothelial specific Tie1 deletion reduces mobilization at steady state and G-CSF-induced 
stimulus yet does not affect HSPC expansion  
(A) Schematic representation of experimental model. Endothelial-specific Tie1 deletion was induced via 
tamoxifen administration. Mice received either G-CSF or equal volume of NaCl at d0 and sacrificed at day 3. (B) 
Absolute HSPC numbers in BM and (C) spleen at steady state (n=6-10; Mann-Whitney test, *; p<0.05). (D) 
Absolute HSPC numbers in BM, (E) spleen and (F) blood at G-CSF stimulation. Data are shown as mean±sd (n=4-
10; Mann-Whitney test, *; p<0.05).  
In order to explore the roles of Tie1 receptor in HSPC egress and mobilization, tamoxifen was 
administered according to the established protocol (Fig. 16A) and Cre/Lox recombination efficiency 
was determined by Tie1 gene expression analysis in whole bone marrow (WBM) (Fig. 16D). Upon 
endothelial Tie1 deletion, Ang2 protein levels in serum was elevated at steady state as well as in G-
CSF-treated Tie1iECKO mice (Fig. 16B-C). Moreover, gene expression analysis in the WBM was carried 
out in order to investigate the behavior of Tie2 receptor and Angiopoietin-1 ligand upon G-CSF 
stimulation and endothelial cell Tie1 deletion. Similar to Tie1, Tie2 receptor was upregulated upon G-
CSF stimulation and downregulated in the absence of Tie1 (Fig. 16E). The gene expression of the 
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agonistic ligand Ang1, was downregulated upon G-CSF stimulus and even more so in Tie1iECKO mice 
compared to WT (Fig. 16F).  Moreover, the panvascular gene, Pecam1 (CD31) was significantly 
increased upon G-CSF stimulus indicating the vascular compartment’s involvement in the process of 
HSPC activation and mobilization. However, Pecam1 was significantly downregulated in Tie1iECKO mice 
compared to WT mice upon G-CSF treatment (Fig. 16G). The gene expression of the intercellular 
junction marker, VE-Cadherin (Cdh5) and the tight junction marker, Claudin 5 (Cldn5), did not 
significantly differ between WT and Tie1iECKO mice. However, upon G-CSF stimulus, gene expression of 
VE-Cadherin was downregulated whereas the opposite occurred for Claudin 5 (Fig. 16H-I).    
 
 
Figure 16: Endothelial specific Tie1 affects gene expression at steady state and G-CSF mobilization in 
the bone marrow  
(A) Schematic representation of experimental model. Endothelial-specific Tie1 deletion was induced via 
tamoxifen administration. Mice received either G-CSF or equal volume of NaCl at d0 and were sacrificed at d3. 
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(B) Ang2 protein concentration in serum of WT and Tie1iECKO mice at steady state and (C) G-CSF stimulation 
(n=4-8; Mann-Whitney test, **, p<0.01). Whole bone marrow gene expression via RT-qPCR of (D) Tie1, (E) TEK, 
(F) Angpt1 and vascular and adherens markers (G) Pecam1, (H) Cdh5, (I) Cldn5. Data are shown as mean±sd 
n=4-8; Mann-Whitney test, *; p<0.05, **; p<0.01, ***; p<0.001). 
In order to assess HSPC proliferation, mice were induced with tamoxifen, mobilized with G-CSF and 
received EdU (1mg/mouse) intraperitoneally 24h prior to sacrifice (Fig. 17A). Bone marrow HSPCs 
were analyzed using “LSK” markers by flow cytometry. EdU incorporation into dividing LSK cells 
showed no difference between WT and Tie1iECKO mice (Fig. 17B).  
 
 
Figure 17: Endothelial specific Tie1 deletion does not affect HSPC proliferation 
(A) Schematic representation of experimental model. Endothelial-specific Tie1 deletion was induced via 
tamoxifen administration. Mice received either G-CSF or equal volume of NaCl at d0 and sacrificed at day 3. 
Mice receive EdU (1mg/mouse) 24 h prior to sacrifice for HSPC proliferation quantification. (B) Quantification of 
EdU positive LSK cells in WT and Tie1iECKO mice at G-CSF (day 3) stimulation determined via flow cytometry. Data 
are shown as mean±sd (n=5-7; Mann-Whitney test). 
BM vascular endothelial barrier function was assessed using the Evans Blue Dye (EBD) assay. Here, 
extravasation of the circulating low molecular weight dye Evans Blue from BM vessels to the 
surrounding tissue is analyzed by measuring the absorbance of the dye extracted from femurs. Upon 
G-CSF stimulus, there was no detectable difference in absorbance ratio between WT and Tie1iECKO 
mice.  
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(A) Schematic representation of Evans Blue dye i.v. administration in induced WT and Tie1iECKO mice. Mice were 
sacrificed 4h later and femurs were harvested for colorimetric quantification. (B) Extravasated Evan’s Blue dye 
quantification at G-CSF stimulation. Data are shown as mean±sd (n=7-8; Mann-Whitney test).  
The vasculature was also functionally assessed by performing an HSPC homing assay. Transplanted 
HSC and HSPC have the ability to successfully lodge and reach the recipient’s BM. This property can 
be used as an indication of HSC and HSPC functionality as well as an assessment of the recipient’s 
vasculature.  Equal numbers of BM Lin- cells were injected intravenously into WT and Tie1iECKO mice 4 
hours prior to sacrifice at G-CSF day 3. Flow cytometry analysis of the BM indicated that a reduced 
number of Lin- cells reached the recipient Tie1iECKO BM further supporting the notion that Tie1 acts as 
a vascular gate-keeper for HSPC. 
 
 
Figure 19:  Absence of endothelial Tie1 reduces efficient homing of donor undifferentiated cells  
(A) Schematic representation of homing experiment in WT and Tie1iECKO mice at steady state. Lineage- BM cells 
from CD45.1 donor mice were collected and transplanted in WT and Tie1iECKO (CD45.2) mice. Recipient mice 
were sacrificed after 4h and femurs were processed for flow cytometry. (B) Flow cytometry quantification of 
donor Lineage- cells in recipient mice femurs. Data are shown as mean±sd (n=5-6; Mann-Whitney test, *; 
p<0.05).  
Finally, the femur diaphysis and epiphysis were chosen for imaging and analysis of vascular area and 
dextran-FITC extravasation. WT and Tie1iECKO mice received 10mg/mouse dextran-FITC 70 kDa 
intravenously 4 h before sacrifice. This timeframe allowed for dextran-FITC extravasation from BM 
vessels to surrounding tissues. Endomucin was the vascular marker of choice in the BM due to high 
specificity in sinusoidal vasculature. At steady state, neither diaphysis nor epiphysis had evident 
differences in endomucin staining. Upon G-CSF however, vascular area in Tie1IECKO mice was reduced 
in both regions. In the case of extravasated dextran-FITC, there was no difference between WT and 
Tie1iECKO mice in both steady state and G-CSF models in the diaphysis. In the epiphysis however, there 









Figure 20: Bone marrow vasculature and dextran extravasation in Tie1iECKO mice at steady state and 
upon G-CSF treatment 
(A) Representative confocal images of dextran-FITC 70kD (green), endomucin+ (red) sinusoidal vessels in the 
femur diaphysis and epiphysis. Scale bar indicates 100 μm. Relative vessel area in steady state and G-CSF 
treated (B) diaphysis and epiphysis. Dextran extravasation quantification at steady state and G-CSF treatment in 
(C) diaphysis and epiphysis. White arrows indicate dextran-FITC and endomucin co-localization. Arrows 
indicated extrasazated dextran-FITC. Data normalized to WT. Data are shown as mean±sd (n=4-8; Mann-
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3.6 Tie1 deletion on HSPC reduces short-term BM reconstitution in 
lethally irradiated mice  
Since the receptor’s discovery in the early 90s, it was well accepted that Tie1 is expressed by both 
endothelial cells and immature hematopoietic cells. This study would therefore be incomplete 
without the investigation of the roles of Tie1 expressed in HSPC. In order to get a glimpse of how 
Ang/Tie expression is distributed among separate HSC and multipotent progenitor (MPP) populations 
I reanalyzed the bulk sequencing data produced by Cabezas-Wallscheid et al. (35) and focused on 
gene expression of the components of Ang/Tie signaling family (Fig. 21). The different populations 
were grouped hierarchically according to loss or gain of surface markers. Multipotent HSC with long-
term self-renewal were followed by multipotent MPP1 with short-term self-renewal. MPP2 
population was characterized by the presence of CD48, whereas MPP3 and MPP4 represented 
progeny with myeloid and lymphoid bias respectively. Mean reads per kilobase of transcript per 
million mapped reads (RPKM) of Angpt1 and Tie1 demonstrated a clear correlation between higher 
gene expression and hierarchical order.  
 
Figure 21: Ang/Tie gene expression of different hematopoietic stem and progenitor cell populations 
obtained by bulk RNA sequencing 
Mean RPKM of Angpt1, Tie1, TEK and Angpt2 in hematopoietic stem and progenitor cell populations sorted 
according to surface markers (lower panel). All groups above are also encompassed by the Lineage- Sca-1+ c-Kit+ 
population.  
Although both Tie receptors have been associated with HSC and HSPC, most studies have focused on 
Tie2 as an important receptor for HSC quiescence. In order to investigate the roles of Tie1 expressed 
on HSPC, Tie1flox/flox mice were crossed with inducible Gt(ROSA)26Sortm1(cre/ERT2)Tyj (Rosa-CreERT2) 
mice (Fig. 22). Tie1flox/flox mice were used as controls (Wildtype, WT). For all experiments, Tie1 deletion 
efficiency was evaluated by qPCR in sorted HSPC. Mice with less than 90% Tie1 deletion were 
excluded from analyses.  
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Figure 22: Targeting strategy of the Tie1 locus 
ROSACreERT2 mice were bred with Tie flox/flox mice to achieve global Tie1 receptor deletion.  
Having established that Tie1 expression occured not only on EC but also on HSC and HSPC, the next 
step was to investigate the biological function of the receptor. For this purpose, Tie1 deletion was 
induced on Tie1KO mice and HSPCs were sorted using the “LSK” markers and plated at a concentration 
of 1000 cells per well with two technical replicates per mouse (Fig. 23A). The LSK cell-derived colonies 
were counted on week 1 showing a clear decrease in absolute numbers of colonies in the absence of 
Tie1 (Fig. 23B). The colonies were further categorized according to their appearance, size and color. 
Interestingly, colonies composed of macrophage progenitors (CFU-M) and the combination of multi-
potential granulocyte, macrophage and megakaryocyte progenitor cells (CFU-GEMM) did not show a 
significant difference in colony numbers. However, in the case of granulocyte progenitor cells, a 
decreased number of colonies was counted in cells derived from Tie1KO mice suggesting that Tie1 has 
a role in the granulocytic progenitor differentiation (Fig. 23C). On week 2, the re-plated cells 
generated fewer colonies due to diminishing hematopoietic potential of stem cells. However, the 
result of fewer colonies in Tie1 deleted progenitors was still evident further supporting the notion 
that Tie1 is important in granulocytic differentiation (Fig. 23D-E).  
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Figure 23: Deletion of Tie1 on HSPC leads to reduced colony formation  
(A) Global Tie1 deletion was induced in Tie1KO mice with the administration of tamoxifen every other day (5 
times in total). After a washout period of 15 days, mice were sacrificed and their BM was processed and stained 
for FACS. Sorted HSPCs were plated at a concentration of 1000 cells/1mL MethoCultTM medium within 6-well 
plates. Derived colonies were counted after 1 week. Cells were then re-plated a concentration of 10.000 
cells/well and derived colonies were counted 1 week later. (B) Total colony counts and (C) absolute number of 
identified colony type. (D) Total colony counts and (E) absolute number of identified colony type on week 2. 
Data are shown as mean±sd (n=4; Mann-Whitney test, *; p<0.05). (abbreviations see text)  
The next step was to assess the functional roles of Tie1 in vivo. One of the most important properties 
of hematopoietic stem and progenitor cells is that when transplanted into an irradiated recipient they 
possess the ability to reinitiate blood cell production. The in vivo clonal repopulating assay was 
established by Till and McCulloch and since then it has been altered and evolved according to 
scientific questions (206). Global Tie1 deletion was induced as described before and BM HSPCs were 
sorted from WT and Tie1KO mice. There are two identifiable alleles for Ptprc (CD45 leukocyte antigen), 
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CD45.2 mice were used for in vivo tracking of donor and host immune cells. Primary transplantation 
took place as equal numbers of either WT or Tie1KO HSPCs were intravenously injected into lethally 
irradiated (9Gy) CD45.1/B6 mice. Blood was withdrawn every 4 weeks and processed for FACS. 
Donor-derived cells were distinguished from recipient cells due to CD45.1/CD45.2 isoform difference. 
The next goal was to assess the long-term reconstitution efficacy of Tie1-deleted hematopoietic stem 
cells by means of secondary transplantation. After 12 weeks, recipient mice were sacrificed and 
sorted for CD45.2 WT and Tie1KO HSPCs. Equal numbers of these cells were intravenously injected into 
a second cohort of lethally irradiated (9Gy) CD45.1/B6 mice. Similar to the first recipient cohort, blood 
was withdrawn every 4 weeks and processed for FACS and Hemavet counter analysis (Fig. 24A). Tie1 
deletion efficiency was evaluated via qPCR of sorted HSPCs before transplantation.  In order to 
analyze distinct immune cell populations, fluorescent antibodies against CD45, CD3, CD11b, Gr-1 and 
CD19 epitopes were used. The cell population characterized by CD45+, CD11b+ and Gr-1+ staining 
encompassed neutrophils and monocytes. Although no difference was detectable up until week 8, 
Tie1 deletion on transplanted HSPC led to decreased ratio of CD11b+Gr-1+ population (Fig. 24B). Upon 
secondary transplantation of WT and Tie1KO HSPCs, the same effects is demonstrated by week 8. 
However, it was not detectable at further time-points (Fig. 24B).  
Blood analysis via Hemavet counter was performed during secondary transplantation in order to 
support flow cytometry findings. Tie1KO HSPC transplanted recipient mice had significantly fewer WBC 
compared to control recipients (Fig. 24C). This effect was due to neutrophils (Fig. 24D) and monocytes 
(Fig. 24F) and not apparent in lymphocytes (Fig. 24E), also isolated by CD45+ and CD3+ flow cytometry-
based analysis.  
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Figure 24: Tie1-deficient HSPC are capable of BM reconstitution yet have reduced efficiency in 
generating myeloid cells  
(A) Global Tie1 deletion was induced in Tie1KO mice with the administration of tamoxifen. CD45.1/B6 lethally 
irradiated mice (9Gy) received either 5000 WT or Tie1KO sorted HSPCs. In order to assess long-term 
reconstitution efficiency of Tie1KO HSPCs, secondary (2ry) transplantation was performed and the blood of 
recipient mice was examined for immune cell markers. (B) Flow cytometry analysis of recipient mice blood 
during primary (1ry) and 2ry transplantation. Hemavet counter analysis during 2ry transplantation of (C) WBC, 
(D) neutrophils, (E) lymphocytes, (F) monocytes. Data are shown as mean±sd (n=5-6; Mann-Whitney test, *; 
p<0.05, **; p<0.01).  
 
Competitive transplantation experiments are functional assays that compare hematopoietic stem and 
progenitor cell capacities of two different cell populations within the same BM. Lethally irradiated 
CD45.1/B6 mice received 10.000 sorted HSPCs composed of 1:1 ratio of WT (CD45.1) and Tie1KO 
(CD45.2) cells. The control group was transplanted with 10.000 sorted HSPCs composed of 1:1 ratio of 
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WT (CD45.1) and WT (CD45.2) cells (Fig. 25A). Throughout 16 weeks after transplantation, blood was 
withdrawn in order to determine engraftment efficiency using cell surface markers that distinguished 
donor cells (CD45.2) from the recipient, or host (CD45.1). Deletion of Tie1 on HSPC did not have an 
effect on engraftment compared to the control (Fig. 25B). However, further immune cell marker 
analysis via flow cytometry confirmed previous finding the deficiency of Tie1KO derived immune cells 
to generate myeloid lineages. The percentages of CD11b+F4/80+, CD11b+Ly6G+ and CD11b+Ly6C+, also 
described as macrophages, neutrophils and monocytes respectively, were significantly decreased on 




Figure 25: Tie1 deletion on HSPC does not affect engraftment efficiency in lethally irradiated mice  
(A) Schematic illustration and representative FACS plots of engraftment efficacy. (B) Contribution of WT and 
Tie1KO donor cells (CD45.2) to the blood cells of lethally irradiated WT recipients (CD45.1) over 16 weeks after 
transplantation. (C) Percentages of different lineages derived from donor cells in the blood of recipient mice at 
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4. DISCUSSION 
The BM is a very complex microenvironment in which numerous cell types reside and interact in 
developmental and pathological settings. Historically, scientists acknowledged the importance of EC 
in steady state hematopoiesis and cell trafficking. However, technical obstacles in visualizing the 
tissue’s location within calcified bone hindered further insight. The evolution of modalities, 
microscopy and hematopoietic markers substantially contributed in providing newer evidence in 
terms of blood vessel and BM interactions. Angiopoietin/Tie signaling has been recognized as crucial 
regulator of development, pathological angiogenesis and inflammation. Partially conflicting studies 
have attempted to elucidate the roles of Angiopoietin/Tie signaling in HSC and HSPC maintenance and 
quiescence in the BM (34, 93). Interestingly, Tie receptors are not confined to EC but also on 
hematopoietic stem and progenitor cells as well as a subset of fully differentiated immune cells such 
as macrophages (37, 38, 53). Employing a range of cellular and functional experiments as well as 
genetic mouse models, the present study demonstrates that i) Ang2 facilitates HSPC activation and 
mobilization, yet, vascular integrity and function remains unchanged; ii) Ang2 is important for 
hematopoietic reconstitution after irradiation; iii) Tie1 deletion increases Ang2 in the serum, yet, 
hinders HSPC mobilization and iv) Tie1 deletion in HSPC delays myeloid hematopoiesis in irradiated 
BM.   
4.1 Ang/Tie signaling at steady state and G-CSF stimulus 
G-CSF has been the mobilization agent of choice in clinical transplantation regimens for the past three 
decades (169). The process of BM transplantation by intravenous infusion depends on the ability of 
HSC/HSPC to “home” and engraft in the recipient’s BM. This procedure entails a sequence of events 
including specific molecular recognition, cell-cell adhesion/disengagement, transendothelial 
migration and effective reconstitution of the eradicated BM stem cell niche (168).  The process of 
rolling is mediated by adhesion molecules on HSPC such as VLA-4 (CD49d), LFA-1 (CD11α) and HCAM 
(CD44). The complementary binding partners of these molecules such as VCAM-1 (CD106), ICAM-1 
(CD54), E- and P-selectin (CD62E and CD62P) are found on the surface of BMECs (207). This suggests 
that BMECs play important roles in BM transplantation on a molecular level.  
The Ang/Tie signaling system is poorly studied in the context of BM vasculature and even more so 
regarding HSPC mobilization. A recent study on human data concluded that G-CSF administration led 
to decreased soluble Tie2 level in aphaeresis samples compared to pre-mobilization blood. The 
significant decrease in Tie2 suggests suppression of Angiopoietin-1/Tie2 signaling, ultimately assisting 
in release of HSPC from hematopoietic niches to blood (208). Another patient study evaluating 
several cytokines showed that VEGF concentration increased upon G-CSF administration, whereas 
Tie2, Ang1 and Ang2 levels decreased in the blood serum (209). A more recent study established that 
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low base-line levels of Angiopoietin-2 in patients’ blood correlates with poor mobilization. On the 
other hand, Angiopoietin-1 levels did not differ between good and poor mobilizers (210).  
To investigate the effects of G-CSF stimulus with respect to Ang/Tie signaling in WT mice, blood was 
collected and hematopoietic stem progenitor cells (HSPC) were sorted via flow cytometry at different 
time-points following G-CSF administration. In contrast to Yang et al. (209), an increase rather than 
decrease of Ang2 was observed in blood serum upon G-CSF stimulation. This was expected since it 
had already been reported that Ang2 is profoundly involved in inflammation (31, 211) and 
recruitment of myeloid cells in a β2 integrin-dependent manner (212). Moreover, this finding is in line 
with the Szmigielska-Kapłon et al. study in which the mobilization procedure demonstrates opposing 
development of Ang1 and Ang2 with a decrease and an increase respectively (210). When looking at 
the gradual decrease of Angpt1 expression on HSPCs during the mobilization process, there are 
several aspects that need to be addressed. Initially, this finding fits nicely to the notion that Ang1 
serves as a mediator for HSPC quiescent state (34, 210) which is disturbed by G-CSF leading to HSPC 
detachment, differentiation and mobilization. However, the gradual Angpt1 expression decrease can 
also be attributed to a shift towards more differentiated immune cells populations due to G-CSF. 
Notably, RNA sequencing data from Cabezas-Wallscheid et al. demonstrated the presence of 
Angpt1high HSC at the top of hematopoietic hierarchy. On the other hand, progenitor stem cell 
populations were associated with lower levels of Angpt1 expression (35). The findings of this thesis as 
well as previously-mentioned studies support the notion that upon G-CSF stimulation, Angiopoietin-2 
dominates binding to the Tie2 receptor against Ang1 leading to the disruption of chemotactic 
interaction within HSPC and stromal cells of the BM and the consequent release to the blood.   
4.2 The absence of Ang2 hinders HSPC activation and BM reconstitution 
after lethal irradiation 
Angiopoietins are highly associated with angiogenesis and inflammation. Initially, Ang1 was 
characterized for the ligand’s anti-inflammatory properties and their contribution to maintaining 
vascular integrity and reducing plasma leakage (213, 214). Later on, the stabilizing functions of Ang1 
were also investigated in terms of pericyte coverage and tightening of EC junctions by preventing 
VEGF-induced VE-cadherin phosphorylation (215). The role of Ang2 was historically projected on the 
assumption that it opposes the anti-inflammatory effect of Ang1 and on the fact that it is upregulated 
in many inflammatory diseases including cancer (216-218). However, subsequent mechanistic data 
showed that Ang2 sensitized Tie2+ EC towards inflammatory stimuli such as tumor necrosis factor α 
(TNF-α) (57). In fact, the authors also showed that the absence of Ang2 in mice led to failure of 
leukocyte arrest. Moreover, Ang2 has also been shown to mediate leukocyte trafficking via the 
transformation of capillaries to venules in a mouse airway inflammatory model (219). Previous in vitro 
and in vivo studies have attempted to elucidate the importance of Ang/Tie signaling in HSC functions. 
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BM transplantation assays following in vitro cultivation of HSCs with angiopoietins showed that Ang1 
maintained long-term repopulating activity of HSCs, whereas the addition of Ang2 drastically inhibited 
with the effects of Ang1 (102). Colony formation assays, on the other hand, showed no Ang1 or Ang2- 
induced effects on HSCs (102). 
Previously discussed data and literature on Ang2 in relation to inflammation pose the question: How 
is Ang2 affecting the process of HSPC activation and mobilization upon G-CSF stimulus? To address 
this, WT and Ang2KO mice were treated with G-CSF. The absolute numbers of HSPCs in the BM, spleen, 
blood as well as circulating immune cells were recorded at different time-points (day 1-6) upon G-CSF 
administration. At steady state there was no apparent difference between WT and Ang2KO mice. This 
involved the absolute number of HSPC in different organs as well as the number of immune cells and 
composition of blood. Ang2 deficient mice have been studied in the past for complex lymphatic and 
vascular phenotypes (56). Depending on genetic background, Ang2 related defects involved 
development of chylous ascites, abnormal vessel architecture, malfunctioning lymphatic valves, 
defective vascular remodeling in the eye, dysmorphogenesis of cortical peritubular capillaries in the 
kidney and premature death (56, 220, 221).  
Evidently, Ang2 is not essential for HSC and HSPC maintenance and immune cell generation at steady 
state. Under G-CSF stimulation however, Ang2KO mice showed a reduced response of HSPC activation 
in the BM compared to WT mice. This translates to reduced mobilization from day 3 until slowly 
catching up at day 5 as shown in data obtain from the spleen. This phenomenon could not be 
captured when looking at blood until day 6. This could be attributed to very low numbers of HSPCs 
identified in blood and therefore a higher risk for variability and cell contamination.  
G-CSF affects the survival, proliferation and differentiation of all cells within the neutrophil lineage 
ranging from the HSC to mature neutrophil. Although there is an evident increase in numbers of 
neutrophils in blood through day 6, Ang2KO mice do not present any defects in generating neutrophils. 
This suggests that Ang2 hinders HSPC activation initially, yet does not affect subsequent 
differentiation of neutrophil progenitors as they eventually catch up. Similarly, Ang2 deficiency does 
not significantly affect activation of HSC suggesting that the population affected is restricted to MMP 
cells. On the other hand, when WT mice were pretreated with Ang2 blocking antibody, G-CSF-treated 
mice showed reduced HSPC expansion compared to control mice. This discrepancy between the two 
models may be attributed to the fact that in the genetic model compensatory mechanisms may have 
resulted in a more stable HSC pool. The pharmacological inhibition on the other hand constitutes a 
better representation of a clinical scenario. Besides, it has been shown that Ang2 deficient mice 
display defects in rapid inflammatory response and more specifically, the processes of leukocyte firm 
adhesion and transmigration are affected (31, 57). However, what remains uncertain is whether 
angiogenic signals directly regulate inflammatory processes, or simply mediate and/or amplify 
previous proinflammatory stimuli.  
The co-staining of cells with Ki67 and Hoechst 33342 provide information on proliferation and cell 
cycle status, respectively. The higher percentage of HSPCs and HSCs in G0/G1 phase in Ang2KO mice 
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describes a more quiescent state irrespective of mobilization status. Naturally, the absence of Ang2 
results in a smaller percentage of HPSCs and HSCs in S/G2/M phase regardless of the mobilization 
state. Notably, the discrepancy in cell cycle phases between WT and Ang2KO mice at steady state does 
not affect the overall HSPC and HSC numbers as shown earlier. This may be attributed to the fact that 
the cell cycle population differences are slight and may be insufficient for the detection of smaller 
HSC and HSPC steady state populations. The focus of the study involved two very different, yet 
challenging to distinguish processes: HSPC activation and mobilization. The absence of Ang2 affects 
HSPC activation by hindering the cell cycle. However, the process of retention and mobilization should 
be further discussed. The Cxcl12/Cxcr4 signaling axis is regarded essential for neutrophil homeostasis 
and mobilization (222). Ccxr4 negatively regulates neutrophil release in a cell-autonomous manner 
and therefore its higher expression in HSPCs and HSCs in the absence of Ang2 suggests a higher 
retention capability in the BM stroma. In order to study the process of mobilization alone and 
whether the increased Cxcr4 expression is functionally involved in the retention of HSPCs in the BM, 
AMD3100 was administered to WT and Ang2KO. Notably, the inhibition of Cxcr4 did not hinder HSPC 
mobilization to the periphery. It was therefore evident that Ang2 hindered activation and not 
mobilization of HSPC. Moreover, increased expression levels of Tie2 and Cdkn1a suggest that HSPCs 
are more quiescent in Ang2KO mice. This is in agreement with two landmark studies on Tie2 and 
Cdkn1a in hematopoietic stem cells (34) (223). Finally, the BM vasculature was assessed in terms of 
structure and functionality in the attempt to further validate that Ang2 affected HSPC cell cycle rather 
than BMEC. Developmentally, Ang2 is important for the lymphangiogenic process, yet not critical for 
embryonic survival (224). In adulthood, the roles of Ang2 are studied in pathological contexts such as 
cancer and inflammation. In physiological conditions, Ang2 expression is very low and well-
established vasculatures are not affected. Unsurprisingly, the absence of Ang2 in the BM had not 
affected vasculature structure and leakiness.  
HSC and HSPC are defined by their functional ability to reconstitute a depleted BM. Having shown 
that Ang2 affects HSC and HSPC activation rather than their retention and mobilization, reconstitution 
experiments were also carried out in order to further characterize the importance of the ligand. One 
important yet unavoidable weakness of this model is that irradiation inflicted damage to sinusoidal 
vessels within the BM (225, 226). In patient transplantation research, the roles of neovascularization 
in hematopoietic recovery after irradiation are increasingly recognized (227). The results indicated 
that Ang2 is important, yet not critical for BM reconstitution following lethal irradiation. Hemavet 
counter as well as flow cytometry data show that Ang2 is involved in both branches of hematopoiesis: 
myelopoiesis and lymphopoiesis. Although Ang2 promotes prompt BM reconstitution in terms of 
myeloid and lymphoid immune cells, it is worth considering that the administration of recombinant 
Ang2 in BM ablated patients may involve risks due to the ligand’s association with inflammation and 
metastasis (228). Zhou et al demonstrated that Ang1 secreted by HSC/HSCP and LepR+ cells reduced 
vascular leakiness, yet hindered niche replenishment upon lethal irradiation (93) . Similarly, the thesis 
data suggest that the absence of Ang2 also hinders niche recovery.  
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4.3 Tie1 on endothelial cells controls HSPC egress and mobilization  
The incomplete knowledge of functions of Tie1 receptor and the context-dependent roles of Ang2 
had been limiting progress in understanding how the Ang/Tie system orchestrates vascular stability 
and remodeling in physiological and pathological settings. Yet, the notion that Tie2 signaling is highly 
dependent on the presence and interaction of Tie1 is well accepted (80). Loss of endothelial cell Tie1 
prevents the agonistic actions of Ang1 and Ang2 as shown by Korhonen et al. The authors also 
described that upon inflammation and loss of Tie1, Tie2 and Ang1 expression were downregulated 
whereas, Ang2 was upregulated. The findings of this thesis follow exactly the same pattern as 
Korhonen et al. upon G-CSF stimulation in WBM gene expression analyses.   
Upon steady state, WBM CD31 gene expression is unaffected by endothelial cell Tie1 deletion. Yet, at 
G-CSF stimulation CD31 gene expression was reduced upon endothelial cell Tie1 deletion. Similarly, a 
decreased vessel area in diaphysis and epiphysis was identified in G-CSF-induced Tie1iECKO mice as 
shown by endomucin staining. La Porta et al. has previously described this phenomenon in tumor 
angiogenesis arguing that endothelial cell Tie1 deletion promoted vascular normalization in mouse 
tumors (229). Moreover, the association of decreased vascular markers due to Tie1 deletion has also 
been described as an endothelial-mesenchymal transition (EndMT) (230). Tie1 deletion does not play 
a role in regulating the gene expression of the tight junction molecules, Claudin5 and adherens 
marker VE-Cadherin. Yet, along the lines of the thesis findings, literature has previously described the 
mechanism of G-CSF induced blood-brain barrier stabilization via Claudin 5 reduction (231) and       
VE-Cadherin increase (232). 
In the attempt to elucidate the role of BMEC Tie1 regarding HSPC egress and mobilization, the G-CSF 
model was implemented as described earlier. Within the BM compartment, BMEC Tie1 deletion did 
not induce changes in terms of HSPC activation at steady state and mobilization. These findings were 
confirmed by flow cytometry analysis indicating total HSPC numbers as well as EdU incorporation and 
detection were unchanged. Interestingly, BMEC Tie1 deletion resulted in decreased numbers of 
egressed or mobilized cells in the periphery suggesting that the BM vasculature acts as gatekeeper for 
HSPC. As discussed above, several studies support the notion that BM vascular permeability and HSC 
cell cycle status are not correlated. Similarly, data on mobilized Tie1iECKO mice also demonstrate a 
“tighter” vasculature with no EdU incorporation effect on HSPCs. Data on egressed HSPCs at steady 
state in blood are not shown. Previous analyses showed that egressed HSPCs are very low in number 
in the absence of mobilization stimulus and therefore prone to cell population contaminations and 
errors in interpretation.  
Evans blue dye (EBD) has been traditionally applied for various diagnostic purposes as well as 
estimations of blood volume and vascular permeability. EBD properties stem from its high water 
solubility, slow excretion and its tight binding to serum albumin resulting to a 69kDA protein tracer 
(233). In the attempt to further characterize BM vascular permeability in G-CSF-mobilized Tie1iECKO 
mice, EBD was intravenously injected in experimental and control mice 4 hours prior to sacrifice. 
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Formamide extraction of EBD from femurs and photometric estimation showed no difference in 
vascular leakiness based on EBD extravasation. This finding can be attributed to several factors. As 
mentioned earlier, BM vasculature is fenestrated and EBD bound to albumin constitute a molecular 
weight of 69kDa. HSPC as significantly larger in size (3-7μm) and alterations in BM vasculature that 
restrict HSPC trafficking might not be identifiable by EBD extravasation (234). Moreover, EBD assays 
have traditionally been assessing functionality of continuous blood vessels especially during 
pathological settings such as tumor and inflammation (235, 236). Reduced functional integrity is 
associated with leakier phenotypes. In the contrary, this thesis discusses that Tie1iECKO mice possess a 
“tighter” vasculature which reduces but does not exclusively prohibit HSPC trafficking.  
Besides having the capacity to dynamically egress and mobilize, HSPC are also able to return to the 
BM. The homing process is a good indication of HSPC functionality as well as BM vasculature 
permeability (25, 237, 238). The decreased number of successfully homed Lin- donor cells in Tie1iECKO 
compared to WT mice enhances the evidence that EC Tie1 deletion leads to a “tighter” vasculature. In 
comparison to the EBD assay, this approach is more sensitive to changes in vasculature and therefore 
more representative due the assessment of vessel permeability with BM cells rather than low 
molecular weight dyes.  
At first glance, both mobilization phenotypes observed in Ang2KO and Tie1iECKO mice may appear 
similar due to reduced numbers of HSPC in the periphery. Based on the reduced activity of HSPC in 
Ang2KO mice, the increase of Ang2, both at mRNA as well as protein level in the serum in Tie1iECKO mice 
suggests that HSPC mobilization would be enhanced. On the contrary, data show that Tie1iECKO mice 
have reduced numbers of HSPCs in the periphery. These seemingly unfitting results may be attributed 
to the fact that Ang2KO and Tie1iECKO mice exert mobilization phenotypes on different cell types. 
Initially, the lack of Ang2 affected HSPC whereas deletion of EC Tie1 primarily affected the 
vasculature. Therefore, an increase in Ang2 protein levels may not be sufficient for the HSPC to 
surpass the less penetrable sinusoids in Tie1iECKO mice. 
Tie1 targeting has previously been described in the context of primary tumor therapy by D’ Amico et 
al. The authors assessed the combination of Tie1 deletion and VEGF/VEGFR blocking antibodies and 
saw no additive effect on tumor angiogenesis inhibition. On the other hand, the targeting of Tie1 and 
Tie2 resulted in tumor vessel normalization and growth inhibition (239). La Porta et al also showed 
that Tie1 inhibition not only leads to normalization of primary tumor vasculature, but also hinders 
post-surgical lung metastasis (229). Capillary leak syndrome (CLS) is a potentially life-threatening 
disease induced by endothelial cell damage. G-CSF can cause extravasation of plasma proteins and 
fluid from the blood vessels to extracellular space resulting in the presentation of symptoms of CLS. 
Current treatment regimens focus on alleviating symptoms since there is no known cure. 
Manipulation of vascular permeability may therefore be a desirable prospect since therapeutic 
targeting of Tie1 on endothelial could be an attractive approach for the treatment of CLS.  
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4.4 Tie1 deletion on HSPC delays myelopoiesis 
Tie2 became known as a receptor located on the surface of EC as well as HSC and several studies 
attempted to elucidate its roles in hematopoiesis (34, 38, 240). In addition to that, Tie2-Cre mouse 
lines were established and used to investigate attributes of HSC in mice (241-243). In contrast to Tie2, 
the presence of the orphan receptor Tie1 on HSC has not been investigated in depth. Rodewald et al. 
described Tie1 as dispensable for HSC engraftment and self-renewal (53), yet the significance of the 
receptor’s high expression on HSC remained unexplained. Moreover, the aforementioned study was 
carried out on fetal liver of Tie1-deficient mice due to embryonic lethality. In the present thesis, 
conditional deletion of Tie1 under the ROSA promoter (Tie1KO) was induced via tamoxifen treatment. 
Conditional deletion of the receptor circumvented the issue of embryonic lethality and facilitated the 
study of Tie1 in adult mice. HSPCs were isolated via FACS using the LSK markers. Tie1KO and WT HSPC 
were used in a series of functional experiments including in vitro serial colony forming unit (CFU) 
assays and in vivo serial and competitive BM transplantations. The purpose to these experiments was 
to investigate the importance of Tie1 receptor on HSPC in the processes of differentiation and BM 
replenishment after lethal irradiation.  
Colony-forming unit assays are the most common in vitro manipulation for hematopoietic progenitor 
cells. Tie1KO HSPC appeared to have a disadvantage in clonal colony expansion compared to WT HSPC. 
This effect was mostly detectable in granulocyte progenitor cells. Long-term assessment of Tie1KO and 
WT HSPC resulted in a less pronounced difference in the overall number of colonies, yet Tie1KO 
granulocytic progenitor colony counts remained significantly fewer than WT HSPC-derived colonies. 
These findings constituted the building ground for the consequent in vivo functional assays. BM 
transplantation experiments designed to evaluate relative fitness of donor HSPC against known 
competitor HSPC are a widely used tool for assessing stem cell fitness. Competitive transplantations 
are highly sensitive making it more likely to detect moderate changes in stem cell fitness and benefit 
from having an internal technical control regarding the efficiency of irradiation and injection (244). 
Yet, results can be misleading as the competitor cells can rescue leading to the survival of all recipient 
mice. Therefore, results should be complemented with a non-competitive setting as shown in the 
present thesis. In the serial transplantation scenario, lethally irradiated recipient mice received either 
WT or Tie1KO HSPCs. Interestingly, Tie1 absence of HSPC is more pronounced during primary than 
secondary transplantation. Notably, the CD11b+ Gr1+ population which describes a variety of myeloid 
cells such as monocytes, granulocytes and neutrophils is significantly decreased during primary 
transplantation. This effect diminished during the progression of secondary transplantation 
suggesting that Tie1 does not affect long-term BM reconstitution.  Throughout 16 weeks of 
competitive transplantation, Tie1KO HSPC did not show a disadvantage compared to WT HSPC in terms 
of engraftment efficiency. This suggests that Tie1 is not essential for the reconstitution of an ablated 
BM. Yet, further flow cytometry analysis of different immune populations showed that Tie1KO HSPC-
derived myeloid populations were decreased compared to the control in blood. These data along with 
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Table 1 Chemicals 
Company 
PanReac AppliChem (www.itwreagents.com) 
Carl Roth (www.carl-roth.de)   
Merck (www.merk.de)   
Roche (www.roche-apllied-science.com)   
StemCell Technologies (www.stemcell.com) 
Thermo Fisher Scentific (www.thermofisher.com) 
5.2 Cell culture reagents 
Table 2 Cell culture reagents 
Reagent  Company 
MethoCult™ GF M3434 StemCell Technologies 
Dulbecco’s phosphate buffered saline (PBS) PAA Laboratories 
Fetal calf serum (FCS), heat inactivated PAA Laboratories 
Trypan blue Thermo Fisher Scientific 
5.3 Primers and Oligonucleotides  
5.3.1 Genotyping primers 
Table 3 Genotyping primers 
Genotype Primer name Sequence 
Ang2KO 
mL2-5’ GTD CTG GGA TCT TGT CTT GGC C 
mL2-intron1US1 CTT CTC TCT GTG ACT GCT TTG C 
Neo3’ds85 GAG ATC AGC AGC CTC TGT TTC 
Tie1flox/flox 
LoxP1 for ATGCCTGTTCTATTTATTTTTCCAG 
LoxP1 rev TCGGGCGCGTTCAGAGTGGTAT 
Cdh5-CreERT2 
Cre for CAGGGTGTTATAAGCAATCCC 
Cre rev CCTGGAAAATGCTTCTGTCCG 
Actin for CAATGGTAGGCTCACTCTGGGAGATGATA 
Actin rev AACACACACTGGCAGGACTGGCTAGG 
Rosa-CreERT2 
AU-RCE -1 AAA GTC GCT CTG AGT TGT TAT 
AU-RCE -2 GGA GCG GGA GAA ATG GAT ATG 
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5.3.2 TaqManTM probes for RT-qPCR 
All TaqManTM probes were purchased from Thermo Fisher Scientific 
Table 4 TaqManTM probes for RT-qPCR 
Target gene (ms) Ordering number 
B2m Mm00437762_m1 









5.4 PCR/RT-qPCR reagents, nucleotides and buffers 
Table 5 PCR/RT-qPCR reagents, nucleotides and buffers 
Reagent  Company 
100 bp DNA Ladder plus Fermentas 
10 x Coral Load PCR buffer Qiagen 
Direct PCR Lysis Reagent PeqLab 
DNase/RNase free H2O Gibco 
dNTP mix (10mM each) Fermentas 
Ethidium bromide Roth 
Taq DNA polymerase (5U/μl) Qiagen 
TaqMan® Fast Advanced PCR Master Mix Thermo Fisher Scientific 
 
5.5 Company kits 
Table 6 Company kits 
Reagent  Company 
Arcturus PicoPure RNA Isolation Kit Thermo Fisher Scientific 
EdU-Click 488 Baseclick 
Fixation/Permeabilization Solution Kit BD Biosciences 
Lineage cell depletion kit BD Biosciences 
Mouse/Rat Angiopoietin-2 Quantikine ELISA Kit R&D systems 
Pierce Bicinchoninic acid (BCA) Protein Assay Kit Thermo Fischer Scientific 
Quantitect Reverse Transcription Kit for cDNA Synthesis Qiagen 
GenEluteTM Total RNA purification Kit Merck 
 
Materials 
- 57 - 
 
5.6 Immunohistochemistry 
5.6.1 Primary antibodies 
Table 7 Primary antibodies 
Antigen  Reactivity Species Conjugate Dilution Source (cat.no) 
C-kit (CD117) mouse rat APC 1:400 BD Biosciences (553356) 
Sca-1 mouse rat APC-Cy7 1:200 Biolegend (108125) 
CD48 mouse rat PE-Cy7 1:200 Biolegend (103423) 
CD150 mouse rat PE-Cy5 1:100 Biolegend (115912) 
CD45 mouse rat FITC 1:400 BD Biosciences (553080) 
CD11b mouse rat PE-Cy7 1:200 Thermo Fisher Scientific (25-0112) 
Gr-1 mouse rat APC 1:200 Biolegend (108412) 
CD19 mouse rat PE 1:200 BD Biosciences (557399) 
CD3 mouse rat APC-Cy7 1:50 Thermo Fisher Scientific (470032) 
CD45.1 mouse rat FITC 1:400 BD Biosciences (553775) 
CD45.2 mouse rat APC 1:400 BD Biosciences (558702) 
Endomucin mouse rat - 1:100 Santa-Cruz (65495) 
Sca-1 Mouse  rat APC 1:100 Thermo Fisher Scientific (17598183) 
DAPI mouse rat - 1:2000 Thermo Fisher Scientific (D1306) 
CD8a mouse rat Pacific Blue 1:200 Biolegend (100725) 
CD45R/B220 mouse rat Pacific Blue 1:200 Biolegend (103227) 
CD11b mouse rat Pacific Blue 1:200 Biolegend (101224) 
Ter-119 mouse rat Pacific Blue 1:200 Biolegend (116232) 
CD3 mouse rat Pacific Blue 1:200 Biolegend (100214) 
Ly-6G/Ly-6C mouse rat Pacific Blue 1:200 Biolegend (108430) 
5.6.2 Secondary antibodies 
Table 8 Secondary antibodies 
 
Reactivity  Species Conjugate  Dilution Source (cat.no) 
Rat IgG Goat AF-546 1:200 Life technologies (A11081) 
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5.6.3 Staining reagents 
Table 9 Staining reagents 
Staining Company 
BSA Gerbu 
EDTA 0.5M pH 8.0 Thermo Fisher Scientific 
Fluorescence mounting medium DAKO 
Gelatin Merck 
Hoechst Dye 33258, 1mg/ml Merck 
Normal goat serum ready‐to‐use (10%) Zymed 
Roti‐Histofix 4% (pH 7) Carl Roth 
Sucrose Merck 
Polyvinylpyrrolidone (PVP)   Merck 
Tissue-Tek O.C.T.TM Compound Scigen 
Triton X-100 Thermo Fisher Scientific 
5.7 Reagents for animal experimentation  
Table 10 Reagents for animal experimentation 
Reagent Company 
AMD3100 Merck 
Mouse anti-human Ang2 ab /IgG Eli Lilly 
Dextran -70 Merck 
Evans Blue dye Merck 
Formamide Merck 
G-CSF (Neulasta) Amgen 
Ketavet  Pfizer 
NaCl solution  Braun 
Rompun  Bayer 
5.8 Solutions and Buffers 
Table 11 Solutions and buffers 
Buffer  Composition 









adjust pH 7.2-7.4 









adjust pH 7.4 




Tris-HCL pH 7.5 
NaCl 
Tween-20 
Tris-Buffered Saline Tween-20 (TBS-T) 10 mM Tris/HCl, pH 7.5 
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Prepared in PBS 








Prepared in PBS 
 
5.9 Consumables 
Table 12 Consumables 
Consumables Company 
96 well plates Steinbrenner Laborsystem 
384 well plates 4titute 
6-well plates  Sarstedt 
12- well plates Sarstedt 
Cannula (18G, 19G, 27G, 30G)  BD 
Cell culture dishes (10cm, 15cm)  TPP 
Cryotubes  Carl‐Roth 
FACS tubes  BD Biosciences 
Filter containing pipette tips  Biozym 
Freezing box  Thermo Scientific 
Hematocrit capillaries Na-hep Hirschmann 
Insulin syringe  BD 
Lancets Solofix Braun 
LS Columns MACS® Thermo Fisher Scientific 
Microscope cover glasses  VWR international 
Microscope glass slides  Menzel‐Gläser 
Pipette tips  Nerbe 
qPCR plates (96-well)  Biozyme 
qPCR plates (384-well)  Roche 
Reaction tubes (0.5ml, 1.5ml, 2ml)  Eppendorf 
Reaction tubes (15ml, 50 ml)  Greiner 
Round bottom 96 well plate  Greiner 
Sealing foil  Applied Biosystems 
Sterile pipettes  Corning 
Sterile filters  Renner 
Syringes  Dispomed 
Tissue cultures 6-well plates  Greiner 
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5.10 Equipment 
Table 13 Equipment 
Equipment Company 
Canto II BD 
Cell culture hood  Thermo Fisher Scientific 
Cell culture incubator Thermo Fisher Scientific 
ConfoCor 3 LSM 710 Zeiss 
Centrifuge Thermo Fisher Scientific 
Countess™ automated cell counter Thermo Fisher Scientific 
Hyrax C50 Microtome Cryostat Zeiss 
FACS Aria II BD 
FACS Aria Fusion BD 
Heating block Eppendorf 
Hemavet 950 FS Drew Scientific 
iMark™ Microplate Reader BioRad 
Light cycler 480 Roche 
LSM710 Zeiss 
LSR Fortessa  BD 
Mortar/Pestle 150mm Thermo Fisher Scientific 
MACS Magnetic separators Miltenyi 
Multistep pipette Eppendorf 
NanophotometerR N60 INTAS 
Olympus IX 71 Olympus 
Pipettes ErgoOne 
QIAxcel Advanced System Qiagen Qiagen 
Special accuracy weighing scale Mettler Toledo 
StepOnePlus Real-Time PCR System Thermo Fisher Scientific 
Surgery and dissection tools Fine Science Tools 
Table centrifuge (5417R) Eppendorf 
Thermocycler Applied Biosystems 
Tubes and adapters for flow incubation Carl Roth 
Vortex Neolab 
Water bath Julabo 
5.11 Miscellaneous 
Table 14 Miscellaneous reagents 
Reagent Company 
Collagenase A Merck 
Dispase  Roche 
Ki67 BD Biosciences 
Lysis Solution Merck 
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5.12 Software 
Table 15 software 
Software Company 
Fiji ImageJ 
FlowJo Miltenyi Biotec 
Illustrator CS6 Adobe 
Light Cycler 480 software Roche 
Microsoft office Microsoft 
Prism Graph Pad 
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6. METHODS 
6.1 Mouse experimentation 
6.1.1 Animal welfare 
Angpt2-deficient mice in C57Bl/6 background were kindly provided by Dr. Gavin Thurston. Mice in 
C57Bl/6 background with inducible deletion of Tie1 gene were kindly provided by Dr. Scott Baldwin 
and the B6-Gt(ROSA)26Sortm1(cre/ERT2)Tyj (Rosa-CreERT2) mouse line was kindly provided by Dr 
Thomas Hoffman. To generate Tie1flox/flox mice, a Tie1 floxed targeting vector was constructed based 
on the 129-Sv mouse genomic fragment used by Puri et al. (245). Tie1flox/flox mice were crossed with 
Tg(Cdh5-cre/ERT2)1Rha (Cdh5CreERT2) mice (205) to specifically delete endothelial Tie1 gene and B6-
Gt(ROSA)26Sortm1(cre/ERT2)Tyj (Rosa-CreERT2) for inducible global deletion (Table 1). Induction of 
Cre recombination was carried out by administration of tamoxifen according the protocol indicated 
on each experiment. C57BL/6-Ly5.1 and C57BL/6N mice were purchased from Charles River. Female 
8-12-week old mice were used in all experiments unless stated otherwise.  
Animals were housed in sterile cages maintained in temperature controlled rooms and had access ab 
libitum autoclaved food and water. All animals were monitored daily for signs of illness. Mice were 
euthanized via rapid cervical dislocation of spinal cord unless stated otherwise. Part of the tail was 
taken for re-genotyping.  
All animal experiments were carried out according to the guidelines of the local Animal Use and Care 
Committees and were approved by the local regulatory committee Bezirksregierung Karlsruhe, 
Germany (G82/18 and G78/19). 
Table 16 In-house mouse lines 
GOI Short 
name 
Full name Induction Purpose 



















6.1.2 Cre recombination induction  
To induce Tie1 deletion in the Tie1iECKO and Tie1KO mouse lines, both control and mutant animals were 
intraperitoneally treated with five doses of 2mg tamoxifen (Merck) dissolved in ethanol/peanut oil.   
6.1.3 HSPC expansion and mobilization 
6.1.3.1 G-CSF-induced expansion and mobilization 
For HSPC expansion and mobilization, mice were received a single subcutaneous dose of 100 μg 
PEGylated human recombinant G-CSF (Neulasta®, Amgen) solution in 100 μL. Control mice were 
treated with 100 μL NaCl subcutaneously. Animals were euthanized at indicated time-points via 
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intraperitoneal (i.p) injection of Ketamin/Xylazin (120mg/16mg per kg). Blood was collected via heart 
puncture. The spleen and two femurs were also collected for analysis via flow cytometry. 
6.1.3.2 AMD3100-induced mobilization 
AMD3100 (Merck) was diluted in NaCl and administered i.p. at a dose of 5 mg/kg 1hour prior to 
sacrifice. As in section 6.1.3.1, mice were euthanized via Ketamin/Xylazin and blood was collected for 
analysis via flow cytometry.   
6.1.4 Ang2 antibody treatment 
Neutralizing rat anti-Ang2 antibody or rat IgG (Eli Lilly) was injected i.p. twice in a week at 20 mg/kg 
per mouse. As in section 6.1.3.1 mice were euthanized via Ketamin/Xylazin administration. Blood, the 
spleen and two femurs were then collected for flow cytometry analysis. 
6.1.5 Proliferation assay 
BM cells were isolated from mice 2 days after G-CSF treatment and stained for LSK, CD150 and CD48. 
Cells were fixed and permeabilized with the BD Cytofix/Cytoperm Kit and stained for Ki67 (BD 
Biosciences). After counterstaining with Hoechst33342, BM HSCs and HSPCs were analyzed via flow 
cytometry. 
6.1.6 EdU proliferation assay 
HSPC cell proliferation in induced female 8-12 week old WT and Tie1iECKO mice was measured 
performing an EdU incorporation assay. A Click-iTTM reaction is performed as proliferating cells 
incorporate 5-ethyl-2’-deoxyuridine (EdU) instead of thymidine during DNA synthesis. EdU can be 
detected due to a fluorescent label. Two days after G-CSF administration, EdU-AF488 was injected 
intraperitoneally at a dose of 1mg/mouse 24h prior to sacrifice. Two femurs were collected and 
processed for staining with LSK markers. Acquisition was performed on a BD Canto II and results were 
quantified using Flowjo software.  
6.1.7 Dextran permeability assay 
Dextran-FITC 70 kDa (Merck) was injected intravenously at a dose of 10mg/mouse 4h prior to 
sacrifice. Femurs were collected and processed for cutting and staining. Stained slides were mounted 
in DAKO fluorescence mounting medium and fluorescent images were acquired on Zeiss LSM710 
confocal microscope. Images were analyzed using Fiji/Image J software.  
6.1.8 Bone marrow transplantation 
6.1.8.1 Ang2KO serial BM transplantation 
Lethally irradiated (2 x 4.5 Gy) 8-12 week old female WT and Ang2KO (C57BL/6N background, CD45.2) 
recipient mice were transplanted with 2x106 BM cells from CD45.1 donor mice. Blood was obtained at 
indicated time-points to determine BM reconstitution via flow cytometry analysis. Recipient mice 
were euthanized at 18 weeks post transplantation to determine engraftment levels via flow 
cytometry analysis. 
6.1.8.2 Tie1KO serial BM transplantation 
Cre recombination was induced via tamoxifen administration to female 8-12 week old WT and Tie1KO 
mice. Mice were sacrificed via cervical dislocation and BM cells from were collected following 
induction. These cells were then processed and stained for LSK staining and sorting. Lethally 
irradiated (2 x 4.5 Gy) 8-12 week old female WT (CD45.1) received 10.000 sorted HSPC from either 
WT or Tie1KO mice. Blood was collected every 4 weeks via the submandibular vein. Equal volumes of 
blood underwent erythrocyte lysis and staining with the appropriate antibodies for the determination 
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of BM reconstitution and engraftment. In order to determine long-term HSPC reconstitution efficacy, 
after 16 weeks mice were sacrificed and their BM cells were collected for HSPC sorting in order to 
perform a secondary transplantation. BM reconstitution and engraftment were determined as 
described above. Mice were euthanized via cervical dislocation.  
6.1.8.3 Competitive BM transplantation 
Lethally irradiate (2 x 4.5 Gy) 8-12 week old female WT (C57BL/6N background, CD45.1) recipient 
mice were transplanted with 1:1 ratio of WT (CD45.1):Tie1KO HSPCs. The control branch received a 1:1 
ratio of WT (CD45.1): Tie1KO (CD45.2) HSPCs. Transplantations were carried out via i.v. administration 
of 5000:5000 sorted HSPCs in 200uL NaCl. Blood was collected every 4 weeks via the submandibular 
vein. Equal volumes of blood underwent erythrocyte lysis and staining with the appropriate 
antibodies for the determination of engraftment efficacy. Mice were euthanized after 16 weeks via 
cervical dislocation.  
6.1.9 Evans Blue Dye Permeability assay 
WT and Tie1iECKO mice were injected with 200 μL of 2% EBD/NaCl solution intravenously into the tail 
vein. After 4 h of circulation of the dye, mice were anesthetized by intraperitoneal injection of 
ketamine (120mg/kg) xylazine (16mg/kg) in NaCl. Completely anesthetized mice were then perfused 
with NaCl via the heart for 5min. Two tibias were used for Tie1 knock-out validation via qPCR and 2 
femurs were collected for crushing in formamide dye extraction at 60oC overnight. The crushed 
fractions were then centrifuged at 2000g for 30min and 70 μL of supernatant was used to measure 
absorption at 620nm and 750nm using an iMarkTM Microplate Reader. Haem pigment correction and 
sample normalization were carried out by subtracting control measurements.  
6.1.10 BM homing assay  
Female 8-12 week old donor WT mice (CD45.1) were euthanized via cervical dislocation and their 
femurs and tibias were collected and crushed using a mortar and pestle. Crushed fraction was 
digested in 3ml of 0.1% Dispase and 0.1% Collagenase A for 15min at 37 degrees and underwent 
negative selection for Lineage- BM fraction. Lineage- BM cells were then injected intravenously into 
the tail of induced WT and Tie1iECKO mice. Mice were euthanized 4h later via cervical dislocation and 
both femurs were collected for crushing, ACK buffer incubation and staining for flow cytometry 
analysis.  
6.2 Cellular assays 
6.2.1 Ex vivo culture of sorted HSPCs for CFU assay 
Induced WT and TieKO mice were euthanized via cervical dislocation and their femurs and tibias were 
collected and crushed with a mortar and pestle. Lineage- BM cells were negatively selected via the 
Direct Lineage Cell Depletion kit (MACS, Miltenyi) and further processed for staining and FACS sorting. 
Sorted HSPCs were plated at a concentration of 1000 cells/1mL MethoCultTM medium within 6-well 
plates. After 1 week, colonies were assessed and counted using an Olympus IX71 microscope. Cells 
were then re-plated a concentration of 10.000 cells/well and new colonies were assessed and 
counted 1 week later. Each biological sample had two technical replicates. The total number of 
colonies and per plate was quantified manually in ≥2 plates for each biological sample on an Olympus 
IX71 microscope. 
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6.3 Immunohistochemistry 
6.3.1 Sample preparation  
For confocal microscopy, femurs were fixed for 2h in 4% paraformaldehyde which was then replaced 
with 0.5M EDTA for 24h followed by 20% sucrose 2% PVP prepared in PBS. Femurs were then 
embedded in EBM medium (8% gelatin, 20% sucrose, 2% PVP in PBS) and kept in -80°C. For 
immunostaining, femurs were trimmed longitudinally until the marrow was visible from highest to 
lowest point using a Zeiss Hyrax C50 Microtome Cryostat. 
6.3.2 Immunostaining  
0.3% Triton X-100 solution was added on the slides and kept at RT for 10 min. After discarding the 
Triton X-100 solution and washing once with PBS, blocking solution was added and slides were kept at 
RT for 30min. After blocking solution was removed, 200 μL of primary antibody solution was added to 
each section and incubated at RT for 2 h. Next, three washes were carried out with PBS at RT. The 
secondary antibody was then added at 200 μL per slide and kept at RT for 1 h. Next, three washes 
were carried out with PBS at RT. Nuclei were stained with DAPI and after three final washes with PBS, 
slides were mounted with appropriate cover slips avoiding bubbles.  
6.3.3 Image acquisition and analysis 
Fluorescent imaged were acquired via Zeiss LSM 710 (10x objective) confocal microscope at the 
imaging core facility of the DFKZ. Image analysis was performed with Fiji/Image J software.  
6.4 Molecular biology methods 
6.4.1 Genotyping PCR 
Genotyping from mouse tissue was performed by PCR of genomic DNA. Tail tips were incubated in 
100 μL Direct PCR Reagent + 10μg Proteinase K at 55oC overnight followed by 20min at 95oC for 
enzyme inactivation. Tail tip lysates were used directly or were stored at -20oC until genotyped.  
Genotyping PCRs for different alleles were carried out using REDTaq® ReadyMixTM and primers as 
listed on tables 17 and 19. Alternatively, the PCR mix was prepared manually as in table 18 and 20.  
Agarose gel was prepared by dissolving 1% (w/v) agarose in 0.5x TBE buffer by heating. Ethidium 
bromide (5 μl/100 ml) was added and the solution was transferred into a cast tray for solidification. 
Samples were loaded onto the gel, which run at 140V for 45min. The 100 bp Generuler Plus DNA-
Ladder (7 μl/well) was used as a size reference. DNA was visible under UV-light and the band size was 
determined relative to the DNA ladder. Alternatively, PCRs were analyzed via QIAxcel Advanced 
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Table 17 Ang2KO  genotyping PCR mix and program 






 1x Step Temperature Time 
dd H2O 9.15 μL 1 94oC 4’ 
RedTaq Mix 2 μL 2 94oC 30” 
Primer loxp1 for (10μM) 0.25 μL 3 60oC 45” 
Primer loxp1 rev  (10μM) 0.25 μL 4 72oC 45’” 
Primer loxp2 rev  (10μM) 0.25 μL 5 72oC 7’ 
DNA 1 μL 6 4oC hold 
Table 18 Tie1flox/flox genotyping PCR mix and program 
Tie1flox/flox genotyping PCR mix  Genotyping PCR Program  
 1x Step Temperature Time 
dd H2O 10.8 μL 1 95 oC 4’ 
Q-Solution 2.60 μL 2 95 oC 30” 
10X Buffer 1.93 μL 3 53 oC 1’ 
MgCl2 0.64 μL 4 72oC 1’  
dNTP 0.64 μL 5 72 oC 5’ 
Primer Tie1fl/fl-5 (5μM) 0.64 μL 6 10 oC hold 
Primer Tie1fl/fl-3 (5μM)      0.64 μL     
Taq 0.13 μL     
DNA 4 μL     
Table 19 Cdh5-CreERT2 genotyping PCR mix and program 
Cdh5-CreERT2 genotyping PCR 
mix 
 Genotyping PCR Program  
 1x Step Temperature Time  
dd H2O 7.50 μL 1 94°C 2’  
RedTaq Mix 12.50 μL 2 94°C 30”  
MB182R Actin (10µM) 1 μL 3 58°C 45”  
MB182R Actin (10µM) 1 μL 4 72°C 2’  
MB183R Cre (10µM) 1 μL 5 72°C 2’  
MB183F Cre (10µM) 1 μL 6 4°C hold  
DNA 2 μL     
Table 20 ROSA-CreERT2 genotyping PCR mix and program 
ROSA-CreERT2 genotyping PCR mix  Genotyping PCR Program  
 1x Step Temperature Time  
dd H2O 19.4 μL 1 94°C 3’  
10 x Buffer 2.5 μL 2 94°C 30”  
25mM MgCl2 0.75 μL 3 60°C 30”  
dNTP Mix (10mM each) 0.5 μL 4 72°C 30”  
AU-RCE-1 (100μM) 0.2 μL 5 72°C 3’  
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AU-RCE-3 (100μM) 0.2 μL     
Taq 0.25 μL     
DNA 1 μL     
6.4.2 RNA isolation 
6.4.2.1 RNA isolation from WBM  
RNA from whole BM cells was isolated using the GenEluteTM kit according manufacturer’s instructions. 
Femurs and tibias were collected and crushed with a mortar and pestle in the presence of 2ml 
PBS/FCSF 5%. Crushed fraction was then passed through a 100 μm nylon mesh into fresh Eppendorf 
tubes. Following centrifugation at 400 g and 4oC for 10min, the pellet is lysed with 350 μL lysis 
solution. Eventually, RNA was eluted in 30 μL RNase free H2O and stored at -80oC. 
6.4.2.2 RNA isolation from sorted HSPCs  
RNA isolation on sorted HSPCs was performed with the ArcturusTM PicoPureTM RNA isolation Kit. 
Sorted cells were centrifuged at 400 g and 4oC for 10min to form a pellet which was then lysed by 100 
μL Arcturus PicoPure extraction buffer. The protocol was performed according to manufacturer’s 
instructions. RNA was eluted in 11 μL RNase free H2O and concentration was measured via 
NanoPhotometer® N60.  
6.4.3 cDNA synthesis 
cDNA generation was carried out using the Quantitect® Reverse Transcription Kit (Qiagen) according 
to manufacturer’s instructions. Template RNA was thawed on ice and 1 μg RNA was incubated with 2 
μL x DNA Wipeout buffer for 2min at 42oC and the total volume was adjusted to 14 μL adding RNase-
free H2O. The mixture was further incubated with 1 μL reverse transcriptase, 4 μL 5xRT-buffer and 1 
μL RT Primer mix at 42oC for 30min for reverse transcription and 95oC for 3min for inactivation of the 
enzyme. The cDNA was diluted 1:10 in H2O for qPCR reaction. cDNA was kept in -20oC for short term 
storage.  
6.4.4 Quantitative Real Time-PCR (RT-qPCR) 
Relative gene expression was quantified by RT-qPCR based on synthesized cDNA. mRNA transcription 
levels were determined based on TaqManTM- based RT-qPCR. The TaqmanTM mono-color hydrolysis 
method is based on probes labeled with a fluorophore (6-carboxyfluorescein, FAM) at the 5’ end and 
a fluorescence quencher at the 3’ end. The Taq polymerase cleaves the probe resulting in FAM 
fluorescence detection. Reactions were taking place in either 96 or 384-well plates. The reaction mix 
components are listed on Table 6. 
Table 21 TaqManTM RT-qPCR reaction mix 
TaqManTM RT-qPCR reaction mix 
cDNA (1:10 dilution) 3 μL 
TaqmanTM Fast Advanced Master Mix 5 μL 
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TaqManTM probe 0.5 μL 
ddH2O 1.5 μL 
Each reaction was performed in technical triplicates. The RT-qPCR was performed using the 
Lightcycler® 480 System (for the 384-well plates) or the StepOnePlus Real-Time PCR System (for 96-
well plates).  
Table 22 TaqManTM RT-qPCR program 
TaqManTM RT-qPCR program 
Step Temperature (oC) Time (sec) 
Pre-denaturation 95 30 
Denaturation 95 2 
Amplification 60 20 
For analysis, the ΔΔCt method was applied as described in literature(246). This is done by normalizing 
CT values of the genes of interest to the CT values of the housekeeping gene for each sample (ΔCT).  
ΔCT = CTgene of interest – CThousekeeping gene 
The normalized CT valued were then further normalized to CT values of control samples (ΔΔCT).  
ΔΔCT = ΔCTsample of interest – ΔCTcontrol sample 
Respective fold changes were calculated from the ΔΔCT values. 
Fold change = 2-ΔΔCT 
6.5 Protein chemical methods 
6.5.1 Preparation of blood serum 
Blood was collected into 1.5ml Eppendorf tubes is either from the submandibular vein or from the 
heart of anesthetized mice. The tubes were left undisturbed for 30min at RT and then centrifuged at 
1.500 x g for 10min at 4oC. The resulting supernatant was removed and stored at -20oC until used for 
the ELISA assay. 
6.5.2 Protein concentration measurement  
The protein concentration of blood serum was determined by the BCA-assay (Pierce) according to 
manufacturer’s instructions for microplate formats. The working reagent (WR) was incubated with 
the samples for 30min at 37oC protected from light. The microplate was then inserted into an iMark™ 
Microplate Reader and measured at 562nm. Standard values were plotted in order to generate the 
standard curve according to which sample concentrations were determined. 
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6.5.3. ELISA 
Serum was collected from C57BL/6N mice injected with either NaCl or G-CSF at different time-points. 
The concentration of Ang2 in mouse serum was determined with the mouse Angiopoietin-2 
Quantikine ELISA Kit (R&D systems). Absorbance at 450 nm was recorded on an iMark™ Microplate 
Reader.  
6.5.4 Fluorescence activated cell sorting (FACS) 
6.5.4.1 Analysis and sorting of HSPCs 
To isolate BM or spleen cell populations, bones were crushed with mortars and pestles and spleens 
were grinded. Crushed and grinded fractions were filtered through a 100 μm nylon mesh. Blood was 
withdrawn from the heart or the submandibular vein using heparinized capillaries. Blood leukocytes 
were purified by erythrocyte lysis (ACK). Total white blood cell (WBC) counts were assessed using a 
Hemavet 950FS cell counter. For HSC or HSPC flow analysis via flow cytometry, immature cells were 
enriched by erythrocyte lysis and selected via lineage (Lin) markers: CD3, CD8a, Ter119, CD11b, 
CD45R (Biolegend) and LSK-SLAM markers: CD117 [2B8] (BD Biosciences), Sca-1 [7H4L3] (Thermo 
Fisher Scientific), CD150 [TC15-12F12.2] and CD48 [HM48-1] (Biolegend). The Mouse Lineage 
Depletion kit (Miltenyi Biotec) was used for HSPC and HSC sorting. BM sinusoidal endothelial cells 
(BM-SEC) were enriched by lineage depletion as described above and identified by negative selection 
for CD45 and positive staining for CD31 (BD Bioscience) and VEGFR-3 (Thermo Fisher Scientific). 
Osteoblasts and osteoprogenitors were isolated by bone crushing and digestion with collagenase P, 
dispase, DNaseI and trypsin. For blood analysis in BM reconstituted mice, antibodies against CD45 
[30-F11], CD19 [1D3], CD11b (BD Biosciences), CD3 [17A2] (Thermo Fisher Scientific), CD4 [RM4-5] 
(Thermo Fisher Scientific), CD8a [5H10] (Thermo Fisher Scientific), B220 [RA3-6B2] (Thermo Fisher 
Scientific) and Ly-6G/Ly-6C (Gr-1) [RB6-8C5] (Biolegend) were used. For the discrimination of donor-
derived and resident immune cells, rat anti-mouse CD45.1 and CD45.2 (BD Biosciences) antibodies 
were used. Live/dead cells discrimination was achieved via Fx Cycle Violet staining (Thermo Fisher 
Scientific). Cell populations were analyzed on BD LSR Fortessa and sorted using FACS Aria cell sorter. 
Single stained and unstained controls were used for compensation and correct gating strategy. Cells 
were pre-gated to distinguish debris and doublets using FSC and SSC. Acquisition was carried out 
using either a BD Canto II or BD LSR Fortessa and quantification of the analysis using FlowJo software. 
6.6 Statistical analysis 
Statistical analysis was carried out via GraphPad Prism 7 (GraphPad Software). Data are illustrated as 
mean ±SD. Statistical significance between experimental groups was determined using two-tailed 
Student’s t-test, Mann-Whitney test as indicated in figure legends. T-test values ≤0.05 were 
considered statistically significant. *=P<0.05, **= P<0.01 and ***= P<0.001. 
Methods 
 









ABIN2 A20-binding inhibitor of NF-kappa-B activation 2 
ACTA2 Alpha-smooth muscle actin 
ADAM a disintegrin and metalloproteases 
AF  Alexa-Fluor 
ALL Acute lymphoid leukemia 
AML Acute myeloid leukemia 
Ang Angiopoietin 
Ang2KO Ang2 global knock out 
Angptl4 Angiopoietin like 4 
ATP Adenosine Triphosphate 
B B-cell 
BCA  Bicinchoninic acid 
BFU-E Burst-forming unit-erythrocytes 
BM Bone marrow 
BRAF B-Raf-proto-oncogene Serine/Threonine Kinase 
C Celsius 
C57BL/6J  C57 Black 6 
CAR CXCL12 Abundant Reticular  
CCL C-C motif chemokine ligand 
CD31 Cluster of differentiation 31 
Cdh5 Cadherin 5 
cDNA  Complementary DNA 
CFU   Colony forming unit  
CFU-E Colony forming unit-erythroid 
CFU-G Colony forming unit-granulocyte 
CFU-GEMM Colony forming unit-granulocyte, erythrocyte, megakaryocyte, monocyte 
CFU-GM Colony forming unit-granulocyte, megakaryocyte 
CFU-M Colony forming unit-monocyte 
CFU-Mk Colony forming unit-megakaryocyte   
CLL Chronic lymphoid leukemia 
CLP Common lymphoid progenitor 
CLS Capillary leak syndrome 
CML Chronic myeloid leukemia 
CMP Common myeloid progenitor 
COL1 Collagen Type I 
COL2 Collagen Type II 
COMP-Ang1 cartilage oligomeric matrix protein-Angiopoietin 1 
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COX2 Cyclooxygenase 2 
CT  Threshold Cycle 
CXCL12 CXC-chemokine ligand 12 
DMSO  Dimethylsulfoxide 
DNA Desoxyribonucleic acid 
DNase  Deoxyribonuclease 
dNTP  Desoxy nucleotide triphosphate 
DPP4 Dipeptidylpeptidase 4 
E Embrionic day 
EBD Evans blue dye 
EC Endothelial cell 
ECM Extrcellular matrix 
EGF Epidermal Growth factor 
EMCN Endomucin 
EndMT Endothelial-Mesenchymal transition 
eNOS endothelial nitric oxide synthase 
ERK Extracellular signal regulated kinase 
ES Embedding solution 
FACS  Fluorescent activated cell sorting 
FAK Focal Adhesion kinase 
Fc Fusion construct 
FCS Fetal Calf Serum 
FDA Food and Drugs Administration 
FGF Fibroblast growth factor 
FITC  Fluorescein thioisocyanate 
FOXO-1 Forkhead Box protein O1 
For Forward 
FSC Forward scatter 
FSP Fibroblast-Specific Protein 
g Gram  
g Gravity (centrifugation context) 
G-CSF Granulocyte colony stimulating factor 
GFP Green fluorescent protein 
GMP Granulocyte-monocyte progenitor 
GOI Gene of interest 
GRB2 Growth factor receptor-bound protein2 
h  Hour(s) 
H&E Hematoxylin/Eosin 
H2O  Water 
HB-EGF Heparin binding-epidermal growth factor 
HSCT Hematopoietic stem cell transplantation 
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HGF Hepatocyte growth factor 
 Hypoxia Inducible Factor 1a 
HRP  Horseradish peroxidase 
HSC Hematopoietic stem cell 
HSPC  Hematopoietic stem progenitor cell 
HUVEC Human Umbilical Vein Endothelial Cells 
i.p Intraperitoneally 
i.v Intravenously 
ICAM Intercellular adhesion molecule 
iECKO Inducible endothelial cell knock-out 
Ig Immunoglobulin 
IGF Insulin growth factor 
IgG Immunoglobulin G 
IHC  Immunohistochemistry 
Il Interleukin 
ILK Integrin Linked Kinase 
kDa  Kilo Dalton 
KO Knock Out 
l  Liter 
LepR Leptin Receptor 
LOX Lysyl oxidase 
LPS Lipopolysaccharide 
LSK Lineage- Sca-1+ c-Kit+ 
LT-HSC Long term hematopoietic stem cells 
Ly6d Lymphocyte antigen 6D G6D 
Ly6g Lymphocyte antigen 6D 
M  Molar 
mAb Monoclonal antibody 
MAPK Mitogen-activated protein kinase 
MDS/MPN Myelodysplastic/myeloproliferative neoplasms  
MET Mesenchymal-Epithelial Transition 
min  Minute(s) 
mm  Millimeter 
MMP Matrix metalloproteinase 
MPP Multipotent progenitors 
ms  Mouse 
MSC Mesenchymal stem cell 
MSPC Mesenchymal stem and progenitor cell 
MYH11 Myosine heavy chain 11 
n  Nano 
Nes Nestin 
NFKB Nuclear Factor kappa-light chain enhancer of activated B cells 
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NG-2 Neural-glial antigen-2 
NK Natural Killer cell 
nm Nanometer 
OPN Osteopontin  
PAR1 Protease activated receptor 1 
PBS  Phosphate buffered saline 
PCNA Proliferating cell nuclear antigen 
PCR Polymerase chain reaction 
PDGF Platelet derived growth factor 
PDGFR Platelet derived growth factor receptor 
PFA  Paraformaldehyde 
pH  Power of hydrogen 
PI3K Phosphatidylinositol-3-kinase  
PKC Protein kinase C  
PMA para-methoxyanfethamine 
POC Primary ossification centre 
PTEN Phosphatase and tensin homologue 
qRT-PCR Quantitative real time polymerase chain reaction 
Rac1  Ras-related C3 botulinum toxin substrate 1 
rev Reverse 
Rho A Ras homolog gene family, member A  
RNA Ribonucleic acid 
RNase  Ribonuclease 
ROS Reactive oxygen species 
RPKM Reads Per Kilobase of transcript, per Million mapped reads 
rpm  Rounds per minute 
RT  Room temperature 
RTK Receptor Tyrosine Kinase 
SCF Stem cell factor 
SD Standard deviation 
MA Smooth muscle actin 
SNS Sympathetic nervous system 
SPS Sucrose preservation solution 
SOC Secondary ossification centre 
SSC Side scatter 
ST-HSC Short term hematopoietic stem cell 
T  T cell 
TAM Tumor associated macrophages 
TBS  Tris buffered saline 
TBS-T  Tris buffered saline with Tween 
TGF Transforming growth factor 
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THPO Thrombopoietin 
Tie  Tyrosin kinase with immunoglobulin-like and EGF-like domain 
Tie1iECKO Tie1 inducible endothelial cells knock out  
Tie1KO Tie1 global knock out 
Tie2KO Tie2 global knock out 
TNF-α   Tumor necrosis factor  α 
TSP1 Thrombospondin 1 
U  Unit 
v/v  Volume/Volume 
VE-Cadherin Vascular endothelial cadherin 
VEGF Vascular endothelial growth factor 
VEGFR Vascular endothelial growth factor receptor 
Vwf Von Wilebrand factor 
w/v  Mass volume (mass concentration) 
WB  Western blot 
WBM Whole bone marrow 
WHO World health organization 
WBC White blood cell 
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